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Foreword 
 
The European Monitoring Centre for Drugs and Drug Addiction has great pleasure in 
presenting its seventh General report of activities to the European Parliament, the Council of 
the European Union, the European Commission and the Member States, following its 
adoption by the Management Board on 17 January 2002. 
 
The report provides a retrospective account of the EMCDDA’s activities and 
accomplishments in 2001, at the start of its new three-year work programme (2001–2003) 
and seven years after its establishment in Lisbon.  
 
The 2001–2003 work programme refocuses the working priorities of the Centre on four main 
areas: monitoring the situation of drug use, monitoring the responses to drug use, 
implementing the EU joint action on new synthetic drugs and monitoring national and 
Community strategies and their impact. Key aspects are to implement and exploit a limited 
set of indicators and core data in the EU so as to provide comparable and reliable 
information on drugs. Policy-makers are redefined as the EMCDDA’s primary target audience 
and efforts have been stepped up to tailor information to their requirements. 
 
The internal reform implemented during the course of the year made profound changes to 
the structure and working methods of the Centre. This proved to be a demanding exercise for 
all involved but was necessary to set up an improved infrastructure within which the new 
activities foreseen in the work programme could be carried out successfully.  
 
My first year as Chairman of the Management Board has been a challenging and exciting 
one. I would like to express my heartfelt thanks to the colleagues on the Management Board 
and the Bureau, the Director and staff of the Centre as well as the national focal point staff 
and members of the Scientific Committee for their support which has enabled the Centre to 
reshape itself and move forward in a more focused direction. 
 
 
 
Mike Trace 
Chairman of the EMCDDA Management Board
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Introduction 
 
Activity in 2001 concentrated on launching the EMCDDA’s third three-year work programme 
(2001–2003). The work programme is consistent with the targets of the EU action plan on 
drugs (2000-2004) with special attention paid to the tasks for which the plan calls upon the 
EMCDDA for action. It also reflects the reform of the agency which was undertaken as a 
follow-up to the recommendations of the external evaluation carried out in 1999. 
 
The work of the EMCDDA is now concentrated in four areas: monitoring the drug situation; 
monitoring responses to the drug problem; implementing the 1997 joint action on new 
synthetic drugs; and monitoring national and Community strategies and policies and their 
impact on the drug situation. These activities are supported by dissemination and 
administrative initiatives and by the Reitox network of national focal points. 
 
Redefining the work priorities of the Centre also necessitated a substantial reorganisation of 
the agency so as to provide an effective structure for the implementation of the work 
programme. New working methods were introduced including project-based planning and 
activity-based budgeting and management. Other key components were also put in place to 
optimise the transition – an internal management coordination committee and a quality 
management and training programme. 
 
Important progress was made during the year on the five harmonised key indicators to be 
implemented in the Member States. Technical tools and guidelines were adopted and work 
commenced on examining an appropriate legal basis for their longer-term stability.  
 
Efforts were also made to improve comparability across the EU on information provided on 
responses to drug use by defining the variables that can be measured in a quantitative way. 
New studies were published in the field of outreach work and on-site testing of synthetic 
drugs. 
 
The Centre’s risk-assessment work on new synthetic drugs remained high on the political 
agenda with the assessment of PMMA launched. Work was carried out with the national focal 
points to strengthen the early-warning system on new synthetic drugs. 
 
The European Legal Database on Drugs (ELDD) was launched containing country profiles, 
texts of law, comparative studies and a comprehensive section on main trends in drug law. 
Data was collected on drug coordination arrangements in the EU and a preliminary overview 
study was published.  
 
Norway joined the Centre in 2001 and I was delighted to welcome them on board. Steps 
have been taken to ensure their full participation in the work of the EMCDDA.  
 
The EMCDDA-Phare cooperation project kicked off early in the year with the aim of providing 
technical assistance to the candidate countries of the CEECs and preparing their integration 
into the activities of the EMCDDA.  
 
The Reitox network, as ever, played a crucial role in the Centre’s work in 2001 via the 
execution of a number of ‘core tasks’ and special projects. An external contractor evaluated 
the activities and products of the focal points, as well as their contribution to the EMCDDA’s 
objectives and results. A decision on the follow-up to the evaluation results will be taken by 
the Management Board in early 2002.  
 
The Centre contributed to the process of evaluating the impact of the Action plan and worked 
with its national focal points and with Europol and its national drugs units to conceive 
appropriate tools for producing two snapshots composed of a set of variables adapted to the 
six priority targets of the EU strategy. The first snapshot will show the situation and 
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responses in place in 1999 prior to the adoption of the EU action plan and will provide a 
baseline against which the progress achieved at the end of the plan in 2004 can be 
measured. 
 
The agency’s 2001 Annual report on the state of the drugs problem in the European Union 
was launched in November at the Spokesman’s Service of the European Commission in 
Brussels. This year, an expanded online version in four languages was also made available 
which provides links to primary sources and supplementary statistical data.  
 
Beyond the four walls of the EMCDDA, cooperation continued with the agency’s six priority 
international partners. In November, the EMCDDA signed a Cooperation Agreement with  
Europol, the purpose of which is to enhance cooperation between the two bodies, particularly 
through the exchange of strategic and technical information.  
 
Dialogue on the drugs problem continued with the Latin American Region. I was pleased to 
attend the Third High Level Meeting in Cochabamba, Bolivia where I discussed ways of 
enhancing cooperation between the EU, Latin America and the Caribbean. In September, it 
was an honour to receive His Excellency the President of Chile, Ricardo Lagos, in the 
context of a State visit to Portugal. A Declaration of Intent expressing a will to initiate 
relations of friendship and mutual cooperation in the field of the prevention and control of 
drug abuse was signed on this occasion. In November, it was an honour to receive His 
Excellency the President of Argentina, Fernando de la Rúa on the occasion of his state visit to 
Portugal and to sign a Joint Statement with the Argentinian drug coordination body 
SEDRONAR, initiating cooperation that could pave the way for the creation of an Argentinian 
Drugs Monitoring Centre.  
 
The year 2001 has been a year of change and transition and was demanding on us all. 
However, I am convinced that the measures put in place provide a secure base from which 
the work of the agency can continue to flourish. I take this opportunity to thank all those who 
contributed to the results achieved. 
 
 
 
George Estievenart 
Executive Director, EMCDDA 
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Work programmes 
 
A new working framework for the EMCDDA was approved at the agency’s Management 
Board meeting in January with the adoption of the three-year and annual work 
programmes for 2001–2003 and 2001. Both programmes reflect the orientations of the 
reform plan adopted by the Board in September 2000 following an external evaluation of 
the agency in 1999. 
 
2001–2003 work programme 
 
The 2001–2003 work programme focuses on: 
monitoring the drug situation;  
monitoring responses to the drug problem;  
 implementing the 1997 Joint action on new synthetic drugs; and 
monitoring national and Community strategies and policies and their impact on the 
drug situation.  
 
These activities are supported by dissemination and administrative initiatives and by the 
Reitox network of national focal points. Special attention is also paid to EU enlargement, in 
accordance with the ‘Enlargement strategy’ adopted by the Board in September 2000. 
 
The work programme is consistent with the targets of the EU action plan on drugs (2000–
2004) with special attention paid to the tasks for which the plan calls upon the EMCDDA 
for action.  
 
Its orientations reflect the reform plan through the implementation of activity-based 
management/budgeting and a project-based approach. 
 
The architecture of the work programme is summarised in two tables:  
• a thematic matrix (see page 9), which provides an overview of the core structure of 
the work programme showing the links between the EMCDDA's main working 
areas (monitoring the situation, responses and impact) and the strategy targets of 
the EU action plan on drugs (2000–2004).  
• a summary of the priority working areas (see page 10), which illustrates the 
working priorities and the role of the EMCDDA and its respective partners in each 
task.  
 
2001 work programme 
 
The 2001 work programme defines the projects to be undertaken in the various thematic 
areas outlined in the 2001–2003 work programme and is the first step towards 
implementing the goals and objectives set out within it. 
 
A budget (43KB) of 9.1 million Euro was adopted for the implementation of the 2001 work 
programme. Of this, 33% of the resources were earmarked for monitoring the drug 
situation; 28% for monitoring responses; 16% for the Reitox network; 15% for monitoring 
strategies and their impact; and 8% for implementing the joint action on new synthetic 
drugs.
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Thematic matrix of the 2001–03 work programme 
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Drug-related social exclusion (cd)) 
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Global availability of illicit drugs (cd) 
 
Availability of illicit drugs at street level (cd) 
 
 
Interdiction measures (cd) 
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Drug-related financial flows (cd) 
 
Flow of diverted chemical  precursors (cd) 
 
Anti money laundering measures (cd) 
Measures against the diversion of chemical 
precursors (cd) 
P 3 
Implementing the EU JA on new synthetic drugs: early warning system and risk assessment  
Monitoring situation and responses concerning NSD (cd) 
P 4 
Monitoring national and Community strategies and policies and their impact on the 
drug situation 
 
National and 
Community strategies 
and policies 
 
(T1, T2, T3, T4, T5, T6) 
 
 
EU action plan  
2000–2004 
 
National and community strategies and policies 
(cd) 
 
Implementation of the EU action plan on 
drugs 2000–2004 
(pi) 
 
ki = key indicators cd = core data  pi = performance indicators 
 
Italic and grey font indicate where the EMCDDA will act as a secondary producer, collecting and disseminating the 
information from other relevant European and international partners who are the primary producers. 
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EMCDDA  3 working Data collection Data collection Establishing tools for
EMCDDA priorities and comparative and comparative the analysis of
added EMCDDA analysis of the analysis of responses the impact of
value compulsory 6 drug situation in in the EU and its MS responses in the EU
priority areas the EU and its MS and its MS
(1) Demand and * Implementing Developing and testing Analysis of the
reduction of demand * the 5 harmonised a core data set on impact of
EMCDDA : epidemiological demand reduction demand reduction
Primary key indicators on the drug situation
information * Developing social core
producer data
in the EU (2) National and Developing and testing Analysis of the
Community strategies a core data set on impact of
and policies * *international, bilateral and international, bilateral
_____ Community policies and Community strategies 
*action plans on the drug situation
* legislation
*activities and agreements
(3) International Supporting the development Supporting the development Analysis of the
cooperation and and testing of a core data set and testing of a core data set on impact of
geopolitics of supply* on producer and * cooperation programmes international cooperation
EMCDDA : transit countries (UNDCP, WHO, CICAD, EC)
Secondary (UNDCP, INTERPOL, 
information EUROPOL, WCO, 
producer CICAD)
in the EU, (4) Control of trade Supporting the development Supporting the development Analysis of the
in partnership in narcotic drugs, and testing of a core data set and testing of a core data set on impact of
with European psychotropic substances on  law enforcement action against trafficking law enforcement
and and precursors * (EC, EUROPOL, WCO, (EC, EUROPOL, WCO,
international INTERPOL, UNDCP) INTERPOL, UNDCP)
organisations
(5) Implications  of Supporting the development Supporting the development Analysis of the
the drugs phenomenon and testing of a core data set on and testing of a core data set impact of
for producer, consumer * market on antimoney laundering anti laundering
and transit countries * illicit financial flows instruments and cooperation measures
(including money (EC, FATF, UNDCP)   (EC, FATF, UNDCP)
laundering) * 
(6) Joint Action  Rapid collection Risk assessment, Assessment for
EMCDDA : of 16 June 1997 and exchange of assessment of the preparation 
Primary on New Synthetic information on New health and social of control measures
information Drugs ** Synthetic Drugs consequences to be implemented
producer ("Early Warning System") of New Synthetic Drugs in MS;
in partnership monitoring of these 
with Europol measures
and EU once taken
organisations
Synthesis and Global synthesis Global synthesis Analysis of
EMCDDA review of the global on the drug situation on drug responses the impact of 
Primary phenomenon in in the EU and its MS in the EU and its MS global responses on
information the EU and MS the global drug situation
producer in the EU and its MS
 *  According to EMCDDA Regulation of 8 February 1993
 ** According to the Joint action of 16 June 1997 on new synthetic drugs
Priority working areas
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I – Programmes, projects and transversal activities 
 
Monitoring of the situation of drug use 
The overall objectives of this programme are to achieve a scientific description and 
analysis of the drug situation in the EU that is reliable, comparable and relevant to policies 
regarding drugs. More specifically it aims:  
 to give an overview of the drug situation in the EU based on collection and analysis 
of the best available data on drug use, supply and their health and social 
consequences and correlates; 
 to improve the comparability and quality of data on prevalence and health 
consequences through the implementation in Member States of 5 harmonised 
epidemiological indicators and through the development at EU level of structures 
and mechanisms to collect, validate, analyse and disseminate data; 
 to identify and conceptualise potential indicators of social consequences and 
correlates of drug use and supply; 
 to analyse and interpret the significance of quantitative and qualitative data on 
trends and differences in prevalence, patterns and consequences of drug use, and 
to assess implications for public health and social policies on drugs; 
 to collaborate with other projects, national focal points, Community bodies and 
programmes and other European and international bodies; and 
 to disseminate results that are reliable and useful for decision-makers, scientists 
and professionals at Community and national levels. 
 
Overview of progress achieved 
Epidemiological data from national reports and other sources were analysed and 
synthesised, in particular for the EMCDDA’s 2001 Annual report. 
Chapter 1 described and compared prevalence, characteristics and trends in drug 
use and its major health consequences, as well as law-enforcement data and 
indicators of drug supply and availability.  
Chapter 3 contained special issues on cocaine and infectious diseases.  
Complementary statistical tables containing standard core data from the Member 
States were compiled and made available online. 
Data for the EMCDDA’s 2002 Annual report were collected from the national focal points, 
and the process of validation begun. 
Performance indicators to measure changes in the drug situation according to the different 
targets of the EU strategy on drugs (2000-2004) were identified, and preliminary data 
provided for the first ‘snapshot’ of the situation in 1999. 
Epidemiological and social data were collected and analysed for scientific meetings, risk 
assessments and monitoring carried out under the joint action on new synthetic drugs.  
 
Improving data comparability and quality 
Five key epidemiological indicators 
Important progress was made regarding the formal adoption of five key harmonised 
indicators of drug prevalence and health consequences to be implemented by Member 
States (1). 
                                                
(1) The five indicators are: extent and patterns of drug use in the general population; prevalence 
of problem drug use; demand for treatment by drug users; drug-related deaths and mortality of drug 
users; and drug-related infectious diseases. 
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 Technical tools and guidelines for the five key indicators were presented to the 
Management Board in January 2001. They were formally adopted in September as 
recommendations from the Centre to the Member States as the technical basis for 
implementing the indicators and for reporting core data to the EMCDDA in 
comparable form. 
 First steps were taken to examine, with the Commission, possible measures to 
facilitate the implementation and longer-term stability of the indicators, including an 
appropriate legal basis. 
Activities were carried out by the EMCDDA to promote and support the process of 
implementing the five key indicators in the Member States. The principle ones were: 
 continued coordination, monitoring and feedback on progress of implementation by 
Member States, including the organisation of the annual EU-level expert groups per 
indicator; 
 a questionnaire to Member States to assess political and institutional commitment 
to implement the 5 key indicators, to ask when data will be available according to 
the guidelines, and to identify major obstacles; 
 development of central epidemiological databases and electronic infrastructures for 
collecting, analysing and disseminating data; 
 discussions to identify synergies with Eurostat and Sanco (DG Public Health – 
health monitoring); and 
 identification of the operational implications for the EMCDDA following adoption of 
the indicators, including measures and means to establish and manage an EU 
epidemiological information system to collect, validate, analyse and disseminate 
good quality, comparable data based on the five key indicators. 
 
Identification and development of core data on social indicators: 
Work commenced on identifying and conceptualising potential indicators and core data in 
new areas of the EMCDDA’s work programme. These topics involve collaboration with 
Europol and are: 
Drug-related crime (especially juvenile and urban delinquency);  
Drug-related social exclusion; and 
Availability of illicit drugs, in particular at street level. 
 
Analysis and interpretation: qualitative and quantitative 
Emerging trends and QED 
Work on emerging trends in drug use and drug problems continued to review and develop 
‘leading-edge’ indicators, with particular emphasis on the analysis of youth media, and 
started the conceptualisation of a theoretical framework to explain and if possible 
anticipate how drug use trends develop and become problematic.  
 
The project also contributed epidemiological and sociological information for the joint 
action on new synthetic drugs. The QED website (Qualitative European Drug Research 
Network), a tool for networking researchers and exchanging information on qualitative 
research on patterns and trends in drug use and related behaviours, especially amongst 
youth, was migrated to the EMCDDA.  
 
TSER modelling network 
This network is based on funding from the European Commission’s targeted socio-
economic research programme (TSER) until the end of 2001. The Centre extended its 
work with research networks of modellers on: prevalence and incidence methodology; 
geographical and temporal diffusion of drug use; and economic modelling, social costs and 
cost-effectiveness.  
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Cooperation 
Cooperation with other European and international bodies included: UNDCP for the 
streamlining of international reporting (ARQ); the Pompidou Group for the treatment 
demand indicator; WHO for the drug-related deaths indicator; the Drugs Coordination Unit 
at the European Commission for the legal basis and coordination; Eurostat for the drug-
related deaths indicator; DG Public Health (Sanco) for the health monitoring programme; 
EuroHIV for the drug-related infectious diseases indicator; Europol for drug-related crime, 
availability, seizures; and Enlargement in preparation for progressive participation of 
candidate countries in the activities of the EMCDDA. 
 
 
Projects 
The different areas covered by the monitoring of the drug situation programme are 
separated into projects and are under the responsibility of a project manager. 
  
Prevalence and patterns of drug use among the general population 
Objectives  
To promote the implementation of the key indicator in Member States including 
  analysing and reporting data received from the Member States  
To plan objectives and tasks for the indicator in 2002 including: developing 
complementary methods to monitor EU drug strategy targets (including reliable 
incidence estimates); ongoing development of an EU system for population survey 
data collection and exploitation; and developing analytical methods to address 
policy questions 
 
Activities 
Guidelines for the implementation of the key indicator were adopted by the EMCDDA 
Management Board in September where the Board concluded that the section on ‘public 
opinion’ of the European Model Questionnaire should not be considered mandatory.   
 
In February, the meeting of European experts took place to revise the draft EMCDDA 
guidelines produced in previous years and to discuss the implementation of a ‘European 
databank on drug population surveys’ as a tool to collect and analyse existing national 
surveys. 
 
The first version of the European databank has been developed, including a model of a 
licence agreement to deposit data with the adequate safeguards for national data holders. 
This prototype contains raw data from existing national surveys reprocessed following the 
EMCDDA guidelines for the key indicator. Reaching agreements with national institutions 
that conducted the surveys took more time than anticipated but it is expected that the 
process will be easier in the future. Ten surveys from four countries have been deposited 
(two from Germany, two from Greece, three from Spain and three from the United 
Kingdom). Other countries are still discussing at national level the terms and procedures 
for depositing data.  
 
A technical handbook was drafted, which summarises work conducted during previous 
years by experts groups, contractors and the EMCDDA for the methodological 
development of the key indicator. The section on population surveys in the key indicators 
database that is currently under construction has begun to be developed.  
 
Data reported by Member States in their national reports were analysed and basic results 
fed into the EMCDDA Annual report and statistical tables. Several proposals for the 
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analysis of data collected through the ‘European Databank’ were developed. During 2001 
only a basic exploratory analysis was conducted on this databank. Further analysis will be 
conducted during the first months of 2002.  
 
Outputs 
The key indicator guidelines adopted by the EMCDDA Management Board 
A technical handbook on EMCDDA guidelines for drug population surveys (to be 
published in 2002) 
First version of the European databank on population surveys on drugs, including 
licence agreements and databases. 
Results of analysis of the Reitox national reports (Annual report), and preliminary 
analysis of the European databank (project report). 
 
For further information on this project see:  
http://www.emcdda.org/situation/themes/drug_use_general_population.shtml 
 
 
Prevalence and patterns of problem drug use 
Objectives 
To promote and assess implementation of the key indicator in Member States and 
improve coverage of methods and quality of estimates 
To analyse and report data provided by the focal points for the Annual report and 
online version 
To promote incidence estimates using draft EMCDDA guidelines 
To produce a final report of the EMCDDA/TSER European modelling network to 
the Commission 
 
Activities 
Data collected through the focal points on the most recent national prevalence estimates 
of and qualitative data on problem drug use, through standard reporting tables and 
national reports, were analysed and described for the Centre’s 2001 Annual report.  
 
An EU expert meeting was held in July to discuss the implementation of the indicator in 
Member States, the quality of current estimates and steps for future improvement. Experts 
participating in the EMCDDA/TSER European Modelling Network also attended this 
meeting and new methods were reviewed to estimate incidence, local level prevalence 
and geographic spread. A report was prepared (project CT.00.RTX.23 ‘State of the art 
regarding national prevalence estimates of problem drug use in the Member States’, 
contractor: IFT). This report gives an overview of the state of implementation and of the 
quality of prevalence estimates and contains a detailed description of national estimations 
in separate country reports.  
 
A final report was received and commented upon ‘Study on incidence of problem drug use 
and latency time to treatment in the European Union’ (project ct.99.ep.05, contractor Univ. 
Rome ‘Tor Vergata’). A prototype database was developed for storage and retrieval of 
prevalence estimation data.  
 
The EMCDDA Scientific Monograph no. 6, ‘Modelling drug use: methods to quantify and 
understand hidden processes’ was finalised and widely distributed. One chapter in this 
monograph, ‘Epidemiology of drug use at macro level: indicators, models and policy-
making’ was adapted and submitted for publication in Bull Narc.  
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Input was given on existing prevalence estimates for the EU action plan on drugs. An 
invited commentary was prepared for the Int J Drugs Policy on a recent UK cohort study of 
drug use in young persons. Draft guidelines were developed for the estimation of 
incidence of problem drug use, and first incidence estimates were collected from some 
Member States.  
 
A report on an EMCDDA network of cohort studies in young problem drug users (project 
CT.99.EP.02B ‘Feasibility study on the implementation of longitudinal studies on changing 
patterns of use, health risks, careers and needs in young problem drug users’, contractor: 
Trimbos Institut) was finalised and distributed to the expert network and a meeting was 
held in November (combined with infectious diseases expert meeting, see under 
‘infectious diseases’). Work was finalised on the development of methods under the 
EMCDDA/TSER European Modelling Network, a progress report was prepared and 
submitted to the Commission (TSER, DG Research) and work on the final report was 
started. Estimates of injecting drug use were derived as part of a draft scientific paper on 
harm reduction coverage (see under ‘infectious diseases’). Results from the key indicator 
and EMCDDA/TSER project were presented and two special sessions organised and 
chaired at the 12th International Conference on the Reduction of Drug Related Harm, in 
New Delhi, India.  
 
Outputs 
Section on problem drug use in 2001 Annual report and statistical tables 
EMCDDA Scientific Monograph no 6, ‘Modelling drug use: methods to quantify and 
understand hidden processes’ 
Epidemiology of drug use at macro level: indicators, models and policy-making’ 
(Wiessing L, Hartnoll R, Rossi C. Bull Narc, in press) 
 5th Intermediate progress report to Commission EMCDD/TSER European 
Modelling Network (issue July 2001) 
 Invited commentary for Int J Drugs Policy (Wiessing LG, in press) 
Final report project CT.00.RTX.23 ‘State of the art regarding national prevalence 
estimates of problem drug use in the Member States’ contractor: IFT 
Final report project CT.99.EP.05, ‘Study on incidence of problem drug use and 
latency time to treatment in the European Union’ (contractor Univ. Rome ‘Tor 
Vergata’ 
Draft guidelines (186KB) for the estimation of incidence of problem drug use 
Final report project CT.99.EP.02B ‘Feasibility study on the implementation of 
longitudinal studies on changing patterns of use, health risks, careers and needs in 
young problem drug users’, contractor: Trimbos Inst.) 
Prototype database for storage and retrieval of prevalence estimation data 
 Input on existing prevalence estimates for the EU action plan on drugs 
 
 
Drug treatment demand 
Objectives 
To promote implementation of the indicator in the Member States 
To produce an EU overview based on existing data, focusing on policy questions 
 
Activities 
The guidelines on the key indicator drug treatment demand were adopted by the 
Management Board. The treatment demand indicator (TDI) protocol was used for the first 
time in the Member States. Further work was carried out on harmonising the operational 
definitions. An experts meeting on treatment demand was held in June 2001 and a basic 
overview of treatment demand data was provided in the 2001 Annual report. 
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Outputs 
Overview of operational definitions of the TDI protocol 
EU overview of treatment demand (2001 Annual report) 
Minutes of the June experts meeting with the first results of the TDI application 
Proposal for future developments 
 
For further information on this project see: 
http://www.emcdda.org/situation/themes/demand_treatment.shtml 
 
 
Drug-related infectious diseases 
Objectives 
To promote and assess implementation of the key indicator in Member States and 
to improve coverage of sources and data quality 
To analyse and report data provided by focal points for the 2001 Annual report  
 Limited coordination of national HCV studies in injectors through annual expert 
meeting (in collaboration with Scieh, Glasgow) 
To disseminate results to scientists and policy makers 
 
Activities 
Drug-related infectious diseases (HIV, hepatitis) data, collected through the focal points on 
the most recent prevalence rates and trends, through standard reporting tables and 
national reports, were analysed and described for the 2001 Annual report.  
 
An EU expert meeting was held in November to discuss the implementation of the 
indicator in Member States and the quality of current data and steps for future 
improvement. A draft final report of the key indicator (project CT.99.EP.09 ‘Project to 
improve collection of data on the key indicator hepatitis B and C and HIV in injecting drug 
users’, contractor: Scieh), giving an overall overview of the state of implementation and of 
quality of HIV/hepatitis data, was updated and extended with the analyses for Annual 
report, and distributed for the expert meeting.   
 
A prototype database was developed for storage and retrieval of prevalence estimation 
data. An invited article was published in Eurosurveillance on the availability of HCV 
treatment for injecting drug users.  Draft guidelines were developed for the collection of 
hepatitis notification data. Preliminary estimates of the economic costs of drug-related HIV 
and hepatitis in the EU were derived as part of the EMCDDA/TSER European Modelling 
Network, a paper was prepared and submitted for publication in Bull Narc. 
 
A paper ‘Estimating coverage of harm reduction measures for injection drug users’ was 
finalised and published in the proceedings of the NIDA/WHO ‘Global Research Network on 
HIV prevention in drug using populations, meeting Durban 2000’. In collaboration with 
WHO, NIDA and Health Canada input was given for the development of a global database 
on HIV prevention indicators, as part of the 2001 meeting of this network in Melbourne, 
Australia. A contribution was prepared for the WHO global review project ‘Evidence for 
Action’ regarding measures to prevent HIV infection and/or injecting drug use in young and 
new injectors in Europe. 
 
Work on EMCDDA Scientific Monograph no. 7 ‘Impact and costs of hepatitis C in injecting 
drug users in the European Union’ was started. Authors were approached, guidelines 
distributed and most chapters received and peer-reviewed (contractor: RIVM).  
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Results on harm reduction coverage were presented at the 12th International Conference 
on the Reduction of Drug Related Harm, in New Delhi, India. Input was given and sessions 
were organised for the Programme Committees of the 13th International Conference on 
the Reduction of Drug Related Harm, in Ljubljana, Slovenia, 2002, and the XIV 
International AIDS Conference, Barcelona Spain 2002. 
 
Outputs 
 Invited article in Eurosurveillance (Wiessing LG, 2001) also available at 
http://www.eurosurv.org/2001/010802.htm#2 
Updated and extended final report project CT.99.EP.09 ‘Project to improve 
collection of data on the key indicator hepatitis B and C and HIV in injecting drug 
users’  
Draft guidelines (106KB) for the collection of hepatitis notification data 
Preliminary estimates of the economic costs of drug-related HIV and hepatitis in 
the EU: paper in (Postma M, Wiessing LG and Jager JC, Bull Narc in press)  
Paper published in proceedings of NIDA/WHO GRN meeting  Durban 2000 
‘Estimating coverage of harm reduction measures for injection drug users’ 
Preliminary estimates of injecting drug use in the EU 
 
 
Drug-related deaths and mortality among drug users 
Objectives  
Drug-related deaths (DRD) 
To promote implementation of indicator in the Member States 
To produce a basic EU overview based on existing data and address policy 
questions 
 
Mortality among drug users (MADU) 
To promote implementation of indicator in the Member States 
To produce a basic overview on mortality among drug users, oriented towards 
policy questions 
 
Activities 
Drug-related deaths (DRD) 
Guidelines for implementation of the key indicator were adopted by the EMCDDA 
Management Board in September. A draft improved version of the guidelines was 
produced by April. This version took into account technical problems observed in some 
countries and also the 10th version of the International Classification of Diseases, which is 
currently being implemented by Member States.  
 
A field trial including data collection at national and EU level (both for General Mortality 
Registries and Special Registries) was carried out. Data collection followed the improved 
version of EMCDDA guidelines, and analysis of the data collected will clarify procedures to 
be followed for ICD-10. A number of countries submitted data late, and the annual expert 
meeting was postponed to 2002.  
 
Data reported by Member States through their national reports were compiled, producing a 
basic EU overview on drug-related deaths for the Annual report, incorporating some 
results from a  previous field trial.  
 
An external contractor (Trimbos Institute, Utrecht, Dutch focal point) has contributed 
substantially to achieving the objectives set for 2001. 
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Mortality among drug users (MADU) 
Guidelines for implementation of the key indicator were adopted by the EMCDDA 
Management Board in September. The annual expert meeting took place in June with 
coordinators of local studies from nine EU countries. A first draft of a handbook on how to 
conduct mortality cohort studies following EMCDDA guidelines was produced. This draft 
will be further elaborated following its submission to an EMCDDA expert group for review. 
 
An overview analysis on mortality cohorts was conducted, based on data from local 
studies. Original raw data were collected and validated centrally in previous phases of the 
project. Some results of this analysis were incorporated in the 2001 Annual report.  
 
An external contractor (Agenzia di Sanita Pubblica, Rome) has contributed substantially to 
achieving the objectives set for 2001. 
 
Outputs 
Drug-related Deaths (DRD) 
Key indicator guidelines  
 Improved version of EMCDDA guidelines for drug-related deaths, including 
guidelines for ICD-10 based Mortality Registries   
Project report presenting results of field trial of improved EMCDDA guidelines 
Results of basic analysis of national reports and  previous field trial (Annual report) 
 
Mortality among drug users (MADU) 
Key Indicator guidelines  
First draft of handbook based on EMCDDA guidelines 
Project report with an overview analysis of data from local studies.  
 
For further information on this project see: 
http://www.emcdda.org/situation/themes/death_mortality.shtml 
 
 
Emerging trends in drug use and drug-related problems 
Objectives  
• To develop concepts, strengthen networking, develop instruments 
• To consolidate the Qualitative European Drug Research network’s website (QED) 
after migration to EMCDDA 
• Theory development 
• Data collection and analysis 
 
Activities 
Activities relating to the first objective included: instigating a youth media pilot project with 
national focal points in some Member States; the early conceptualisation of concepts and 
indicators for emerging trends were developed; and an inventory of mechanisms in Europe 
and Member States for detecting, tracking and understanding emerging trends was 
drafted. 
 
The QED website was migrated to Lisbon, a six-month contract was allocated to an 
external QED animator and the input of expert advisors in Member States secured. 
Training in Dreamweaver computer software was undertaken and an online visitor 
questionnaire developed. 
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Theoretical literature was gathered for review and expert group set up to develop a 
theoretical framework to explain and if possible anticipate how drug trends develop and 
become problematic. 
 
Epidemiological and sociological data from national reports and other sources were 
analysed and synthesised, in particular for: Chapter 3 special issues on cocaine for the 
Annual report; Annexes C and D for MDMA and PMMA for the joint action on new 
synthetic drugs. 
 
Outputs 
 QED website regularly updated, and migrated to Lisbon http://qed.emcdda.org/ 
 Summary of youth media study published online 
http://www.emcdda.org/multimedia/project_reports/situation/youth_media_sum.pdf 
Chapter 3 special issue on cocaine for Annual report 
Annexes C and D for MDMA for the joint action on new synthetic drugs 
Annexes C and D for PMMA for the joint action on new synthetic drugs 
 
For further information on this project see: 
http://www.emcdda.org/situation/themes/emerging_trends.shtml 
 
 
Drug-related crime 
Objectives 
To analyse law-enforcement information sources 
To analyse drug-law offences data 
To analyse existing information on drug users in prison 
To review existing definitions and data on drug-related crime, notably juvenile and 
urban delinquency 
 
Activities 
The information maps on law-enforcement sources 2000–2001 were assessed and 
feedback was provided to the national focal points. A first draft analysis of data sources 
focusing on police/customs interventions on drug law offences, drug seizures and drug use 
amongst criminal populations was carried out. 
 
Drug law offences data and related information were extracted, verified and analysed from 
15 national reports and 15 standard tables. Texts were written and tables and graphs 
generated for the Annual report. 
 
Data on drug users in prison were extracted, checked out and analysed from 15 national 
reports and 15 standard tables. Texts were written and a comprehensive table on 
proportions of drug users in prison across the EU prepared for the Annual report. 
 
A study to ‘Review definitions, data availability and possible indicators of crime related to 
drug use and drug users, notably juvenile and urban delinquency’ was launched. 
 
Outputs 
Assessment reports on information maps 2000–2001 on law-enforcement sources 
(bilateral feedback to NFP’s via e.mail) 
Draft internal report on data sources focusing on police/customs interventions on 
drug-law offences, drug seizures and drug use amongst criminal populations. 
Contributions to the 2001 Annual report.  
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For further information on this project see: 
http://www.emcdda.org/situation/themes/crime.shtml 
 
 
Drug-related social exclusion 
Objectives 
To edit and disseminate 1999–2000 work on ‘Mapping relationships between drugs 
and social exclusion, focusing on minorities’ 
Report to the European Commission on the use of the grant for the meeting in 
2000 on drugs and minorities 
 
Activities 
An executive summary of the report ‘Mapping relationships between drugs and social 
exclusion, focusing on minorities’ (42KB) was written and made available on the EMCDDA 
website. 
 
The 1999–2000 work on ‘Mapping relationships between drugs and social exclusion, 
focusing on minorities’ was assessed for publication by the EMCDDA. The need to 
‘Update and complete the analysis of drug use, consequences and correlates amongst 
minorities’ was underlined and a contracted-out project was launched for this purpose. 
 
A final report on the ‘European expert meeting on valorisation and dissemination of 
information on drugs and social exclusion, focusing on minorities’, held in Lisbon on 28–29 
September 2000, was written and submitted to the European Commission with a 
statement of the expenses. 
 
Outputs 
Executive summary of the report ‘Mapping relationships between drugs and social 
exclusion, focusing on minorities’ (42KB)  
Final report to the European Commission ‘European expert meeting on valorisation 
and dissemination of information on drugs and social exclusion, focusing on 
minorities’, EMCDDA, 15 June 2001. 
 
For further information on this project see:  
http://www.emcdda.org/situation/themes/social_exclusion.shtml 
 
 
Global availability of illicit drugs and availability of illicit drugs at street level 
Objectives 
To identify EMCDDA’s needs, potential indicators and data sources on availability 
of illicit drugs 
To analyse drug seizures, price and purity and existing data on drug availability 
and drug markets from the national focal points 
To disseminate results of TSER funded modelling working group on drug markets 
 
Activities 
The literature available at the EMCDDA was studied for information on definitions and 
concepts of drug availability. Information on questions on drug availability included within 
population and school surveys was requested from the group of national experts on 
population surveys. A first mapping of data potentially available through international 
organisations was carried out. Based on the results from these activities, an internal 
working paper was produced. 
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Data on drug seizures, price, purity, contents of tablets and other drug market-related 
information were extracted, checked out and analysed from 15 national reports and 15 
standard tables. Texts were written and tables and graphs made for the Annual report.  
 
The papers presented by members of the TSER funded modelling working group on 23–
24 October 2000 in Lisbon were gathered and edited for publication of the proceedings on 
the EMCDDA website. 
 
Extra analyses were performed and the report on the ‘Macro-economic analysis of heroin 
markets in the EU and the impact of substitution treatment’ was edited and made available 
on the EMCDDA website together with an executive summary. 
 
Outputs 
 Internal working paper on EMCDDA’s needs, potential indicators and data sources 
on availability of illicit drugs 
Contribution to the 2001 Annual report  
EMCDDA report ‘Expert meeting on drug markets and modelling, 23-24 October 
2000, Lisbon: proceedings’  
EMCDDA scientific report ‘Macro-economic analysis of heroin markets in the EU 
and the impact of substitution treatment’ (352KB) and executive summary (24KB).  
 
For further information on this project see: 
http://www.emcdda.org/situation/themes/availability.shtml 
 
General report of activities 2001 22
Monitoring responses to drug use 
 
Overview of main achievements 
The implementation of the EMCDDA 2001–2003 work programme and the launch of the 
EU action plan on drugs 2000–2004 along with the EMCDDA reform process has 
influenced the work of the ‘Monitoring responses to drug use’ programme (P2). Much 
scientific work has been internalised and the support of national focal points and other 
partners has grown in importance.    
 
In 2001, activities were concentrated on defining core data in the field of responses, i.e. 
Prevention; 
Outreach work and needle exchange; 
Early health responses; 
Treatment; 
Social reintegration; 
Prevention of drug related crime; and 
Supply reduction. 
 
This included determining the limits of and boundaries between the different areas of work, 
both within the programme and between P2 and other programmes. Meetings with all 
potentially involved staff in each project served to clarify this and enhanced the 
cooperation between programmes. 
 
The information on responses to drug use provided to the EMCDDA has so far been 
mainly qualitative, which lies in the nature of the issue and in the lack of scientific 
investigation into these areas. In order to improve comparability across the EU one 
challenge for the work in 2001 was to, as far as possible, define variables that could be 
measured in a quantitative way. Due to the vast and heterogeneous area of responses to 
drug use, the definition of concepts for the various areas turned out to be a main and 
complex task. If by ‘concept’ one would consider a set of criteria such as that an approach 
has an objective, a theoretical background, a defined target group, a specific methodology 
and some kind of evaluation, many activities in the EU would have to be considered as not 
having a concept.  
 
Nevertheless, in order to proceed, compromises have had to be found and a main task 
was to extract common elements from information on various activities in Member States 
in order to define key concepts for the different areas to serve as the basis for information 
collection. In order to find a consensus in reporting, these concepts have to be negotiated 
with national focal points and other players. In most of the areas considerable progress 
has been made in defining concepts, although some are more difficult and more complex 
than others. More established responses such as school prevention and treatment are 
conceptually clearer (if not always clear), whereas defining concepts for outreach work or 
for the prevention of drug-related crime is more complicated.  
 
The decision on and definition of indicators for quantitative core data similarly would need 
to follow a pragmatic approach. The relevance of information, for example relating to main 
concepts and policies, and availability and accessibility of information are key criteria. 
Again, these variables have to be negotiated with national focal points and other partners 
in order to get their acceptance to collect this information which may be quite difficult to 
access on a national level, due to the federal structure of the country, lack of reporting 
mechanisms, reluctance to report, insufficient networks of the national focal points etc.    
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As the task of the EMCDDA is to serve policymakers and professionals, information on 
effectiveness and criteria for success will also have to be established. For example, the 
EU action plan on drugs states as an objective to increase the number of successfully 
treated addicts. Again, the lack of information and quite often a reluctance to evaluate 
makes this task extremely difficult. Through its EDDRA database, various publications and 
other initiatives to promote a systematic planning and evaluation, the EMCDDA attempts 
to contribute to improving the situation. 
 
 
Projects  
The different areas covered by the responses area are divided into project areas and 
under the responsibility of a project manager. 
 
Prevention responses 
Objectives  
To develop indicators on number, coverage, intensity and budgeting of 
school/community prevention interventions 
To draw up a comprehensive overview (1) on models, approaches, objectives, 
theories, concepts and (2) on target groups addressed in school/community 
prevention  
To agree core set of monitoring indicators of interventions and common criteria for 
school/community prevention success 
 
Activities 
An analysis of all prevention programmes contained in EDDRA 
(http://www.reitox.emcdda.org:8008/eddra/) allowed an overview on objectives, models 
and indicators used in 50 leading (i.e. included into EDDRA) prevention programmes in 
Europe (internal Reitox report) to be created. The analysis of community programmes has 
been postponed due to a very low number of EDDRA entries. 
 
In order to complete the information contained in EDDRA (which has several inclusion 
criteria - report quality and minimal evaluation), multilingual, concise questionnaires have 
been created, based on the results of the EDDRA analyses, which were sent to direct 
contacts and national focal points in Member States in order to obtain an overview of other 
existing prevention programmes. Response rates differed greatly between Member States. 
 
An expert meeting on the feasibility of developing indicators for prevention was organised 
in November 2001 with EDDRA managers and additional experts from Member States. 
The findings from both the EDDRA analysis and the prevention survey were discussed 
together with other information available with the aim of better visualising and quantifying 
the intensity, quality and coverage of prevention policies in Member States. Several new 
EDDRA entries related to have been checked and discussed with authors on quality 
criteria. 
 
Outputs 
Minutes of expert meeting, to be published online in 2002 
EDDRA analysis of prevention projects was presented at the VI Alcorcón 
conference on prevention, June 2001, and will be published in the conference 
book. 
 
For further information on this project see: 
http://www.emcdda.org/responses/themes/prevention_schools_communities.shtml 
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Outreach work and needle exchange 
Objectives  
To monitor the definition, priorities and standards for outreach work and needle 
exchange interventions in Member States 
To develop indicators on number, coverage, intensity and budgeting of 
interventions for outreach work and needle exchange 
To obtain a comprehensive overview (1) on models, approaches, objectives, 
theories, concepts and (2) on specific target groups 
To monitor the value of pill testing interventions 
To develop an agreed core set of criteria for the effect and performance of 
outreach work and needle exchange interventions including parameters of social 
inclusion 
 
Activities 
Guidelines for the evaluation of outreach work were finalised, peer reviewed and are 
available online from the EMCDDA website. A report on pill testing in some EU countries 
was finalised and published on the EMCDDA website. 
 
An analysis of all outreach work projects contained in EDDRA  
(http://www.reitox.emcdda.org:8008/eddra/) allowed an overview on objectives, models 
and indicators used in 33 leading (i.e. included into EDDRA) outreach work projects in 
Europe to be created. It shed light on the large range of different outreach work definitions. 
 
As a complement to the information contained in EDDRA multilingual, short questionnaires 
have been created, based on the results of the EDDRA analyses, which were sent to 
direct contacts and national focal points in Member States in order to obtain an overview 
on other projects. Response rates differed greatly between Member States. 
 
An expert meeting on the feasibility of developing indicators for outreach work was  
organised in November 2001 with EDDRA managers and additional experts from Member 
States. The findings from both the EDDRA analysis and outreach work survey were 
discussed together with other information available in Member States, with the aim of 
better visualising and quantifying the intensity, quality and coverage of the delivery of 
outreach work in Member States. Several new EDDRA entries related to outreach work 
had been checked and discussed with authors on quality criteria. 
 
Outputs 
Guidelines for the evaluation of outreach work, downloadable from 
http://www.emcdda.org/multimedia/Project_reports/guidelines_outreach_work_draft.pdf 
and available in printed format. 
Report on the state of the art of on-site pill testing in the EU, downloadable on 
http://www.emcdda.org/multimedia/project_reports/responses/on-
site_pill_testing_sum.pdf (executive summary) 
http://www.emcdda.org/multimedia/project_reports/responses/pill_testing_report.pdf 
(full report) 
http://www.emcdda.org/multimedia/project_reports/responses/pill_testing_fact_files.pdf 
(fact files) 
 
For further information on this project see: 
http://www.emcdda.org/responses/themes/outreach_needle_exchange.shtml 
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Early health responses 
Objectives  
To produce an EMCDDA definition of drug-related early health responses and to 
gather information on case studies according to predetermined criteria following the 
agreed definition. 
 
Activities and outputs 
A kick-off meeting with relevant EMCDDA staff was held in May 2001 and subsequently an 
EMCDDA definition of the concept of drug-related early health responses (EHR) was 
drawn up. Information on drug-related outbreaks complying with the EHR criteria of 
inclusion was then gathered. In July 2001 the Eurosurveillance network identified a drug-
related outbreak in Scotland. The associated early health responses were monitored at the 
EMCDDA by means of information exchange with British public health authorities in order 
to gather in real time relevant information for the project. 
 
A preliminary report on ‘Early health responses – definition and case studies’ was drafted 
in October 2001. The report contains the EMCDDA definition of the concept as well two 
cases studies describing the outbreaks’ characteristics and the associated early health 
responses by public health services to health professionals and to drug users. 
 
For further information on this project see: 
http://www.emcdda.org/responses/themes/early_health.shtml 
 
 
Availability of treatment 
Objectives  
To develop definitions of and standards for treatment in order to classify models 
and approaches used in treatment programmes in EU Member States 
To map and monitor the availability of national drug treatment and its structures 
 
Activities 
A process of extensive data collection was initiated. Data on availability of treatment was 
collected not only through national focal points and their national reports but also through 
other independent sources in order to get as much and as detailed data as possible. The 
data collected from the Member States was thoroughly assessed and analysed. A country 
profile paper was written for each country containing two main items: firstly, outlining the 
most commonly used definitions and concepts to describe and classify treatment 
interventions in the country in question; and secondly, a preliminary overview of the 
availability of treatment in the country. A pan-European overview on the availability of drug 
treatment was drawn up and published on the website.  
 
The Evaluation Instruments Bank was expanded both in terms of number of instruments 
and languages covered. The range of languages represented was expanded from four to 
12 during the course of the year.  
 
Outputs 
A preliminary report on definitions and concepts of treatment as well as its availability was 
published in December at: 
http://www.emcdda.org/responses/themes/drug_treatment.shtml  
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Prevention of drug-related crime 
Objectives  
To complete and disseminate the EMCDDA study Assistance to drug users in EU 
prisons 
To set up preliminary work according to information needs in the field of prevention 
of drug-related crime in line with the EU action plan 
 
Activities 
An abridged version of the study on Assistance to drug users in EU prisons was edited 
and launched on the website with an accompanying press release in August. The full study 
was published as a joint publication with the European Network of Dugs and HIV Services 
in Prisons (ENDHASP) in October and presented at the Prison and community 
conference, held in Brussels 18-20 October. 
 
The results of the study were presented at the 4th European seminar on HIV and hepatitis 
in prison, Lisbon (16–17 March), at the seminar on alternatives to imprisonment for drug-
dependent offenders, Hamburg (1 September) and at the annual ENDHASP conference in 
Brussels, 18–20 October. A session at the drugs coordination unit in Brussels in 
September was dedicated to presenting the study to drug services at the European 
Commission.  
 
Internal work was carried out to establish an EMCDDA definition of the concept of 
prevention of drug-related crime (PDRC), a classification of measures aimed at reducing 
drug criminality and the development of an information gathering tool, the ‘PDRC 
conceptual map’ which will allow further analysis and visualisation of relevant information. 
In order to present this preliminary work, a meeting was held in October and attended by 
the main EU networks. 
 
Outputs 
 Abridged version of the study ‘Assistance to drug users in EU prisons’ 
 ‘Assistance to drug users in EU prisons (book) available from Cranstoun Drug 
Services  
 
For further information on this project see: 
http://www.emcdda.org/responses/themes/assistance_prisons.shtml 
 
 
Social rehabilitation and reintegration 
Objectives 
To develop definitions of and standards for social rehabilitation and reintegration in 
order to classify models and approaches used in EU Member States  
To develop monitoring of social rehabilitation and reintegration structure and linked 
characteristics  
 
Activities 
As a first step, literature and empirical material was gathered through national focal points 
and their national reports as well as other independent sources. Some pre-definitions of 
social rehabilitation and reintegration were drawn up so as to ensure homogenous and 
similar collection of data from Member States. Once these largely similar kinds of data had 
been collected a further analysis, break down and more in-depth overview of the social 
rehabilitation and reintegration interventions at Member State level was carried out. A 
country profile was drawn up containing two main items: firstly, the most commonly used 
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definitions and concepts to describe and classify social rehabilitation and reintegration 
interventions in the country; and secondly, a preliminary overview of the available social 
rehabilitation and reintegration interventions. The overview was drawn up applying the 
concepts and definitions used to describe social rehabilitation and reintegration in the 
respective Member State. A first overall European overview on the availability of drug-
related social rehabilitation and reintegration was drawn up and published on the website.  
 
The term social reintegration is more ambiguous and not so well-defined as, for example, 
treatment. This implies that much of the data collected in Member States might be called 
social reintegration but that the meaning of this term differs so greatly that it is not possible 
to identify similarities let alone compare the data. An external study was launched with the 
aim of clarifying concepts and collecting available data.  
 
Outputs 
A preliminary report on definitions and concepts of social rehabilitation and reintegration 
and on the measures available was published in December at: 
http://www.emcdda.org/responses/themes/social_rehabilitation.shtml  
 
 
Interventions for drug supply reduction 
Objectives  
Bearing in mind the principle of subsidiarity with the EC and international partners, 
the purpose is to identify a first set of information in the field of supply reduction 
through accessing existing databases 
 
Activities 
As the EMCDDA is a secondary producer of information concerning the future 
implementation of the project, preliminary activities have been launched to allow the 
Centre to have access to existing databases. The main goal in 2001 consisted in drawing 
up agreements with the interested international organisations partners so as enable the 
EMCDDA to access the information sources available.  
 
Cooperation agreements or Memoranda of Understanding (MOU) have been established 
with Europol and Interpol and contacts pursued with the World Customs Organisation. The 
agreement with Interpol was signed on 25 September while the one with Europol took 
place on 20 November 2001. Talks with UNDCP on the revision of the current MOU 
(signed with the EMCDDA in 1998) continue. 
 
Concurrently, some contacts with the European Commission and the private sector, 
especially relating to the topic of chemical precursors, are being developed. 
 
Outputs 
Cooperation agreement between Interpol and the EMCDDA, signed by Secretary 
General Mr Roland K. Noble and Executive Director, Mr Georges Estievenart, in 
Budapest and Lisbon on 25 September 2001. 
Cooperation agreement  between Europol and the EMCDDA, signed by Director Mr 
J. Storbeck and Executive Director Mr G. Estievenart in Brussels, on 20 November 
2001.  
  
For further information on this project see: 
http://www.emcdda.org/responses/themes/supply_reduction.shtml 
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EDDRA information system 
Objectives  
To collect reliable and comparable information on high quality programmes on drug 
responses 
To ensure continuous and updated information on on-going programmes 
To provide information on methods and implementation as well as on evaluation 
results 
 
Activities 
The database currently contains around 300 projects, of which 50 were introduced in 
2001. The offline tool has been developed with new and improved functionalities such as 
new export and print functions which facilitate the use and analysis of the data. In parallel, 
a new simplified questionnaire will be used for obtaining information on new programmes 
and projects. A new users’ view has also been designed offering quicker and simpler 
navigation. First qualitative analyses have been carried out this year to highlight best 
practice and develop indicators in the fields of prevention and outreach work at European 
level.  
 
Outputs 
A new scientific manual has been elaborated and is downloadable from the 
EDDRA web pages 
New offline tool with new features 
New revised questionnaire 
New user’s view in the EDDRA website 
 
For further information on this project see: 
http://www.emcdda.org/responses/methods_tools/eddra.shtml 
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Implementing the EU Joint action on new synthetic drugs 
 
Objectives  
To implement article 3 (monitoring new synthetic drugs) and article 4 (assessing 
the risks of new synthetic drugs) of the EU joint action 
To strengthen the Reitox network’s capacity for the Early Warning System (EWS) 
on new synthetic drugs (article 3 of the EU joint action) and to enhance EMCDDA 
coordination 
To fine-tune the Scientific Committee’s guidelines for the risk assessment of new 
synthetic drugs (article 4 of the EU joint action) 
 
Activities 
Monitoring new synthetic drugs (article 3 of joint action) 
This activity involves the permanent collection, analysis and rapid transmission 
(exchange) of information on new synthetic drugs (through the EWS) to the national 
focal points, Europol, the Commission and the European Agency for the Evaluation of 
Medicinal Products (EMEA) in accordance with article 3 of the EU joint action. A joint 
EMCDDA-Europol progress report on PMMA/PMA was prepared and submitted to the 
Council’s Horizontal Working Party on Drugs (HWPD) on 28 May.  
 
Following the Council conclusions of 15 March 2001 for ‘active’ monitoring of GHB and 
continued monitoring of ketamine until the end of 2001, the information on these two 
drugs provided by the national focal points was synthesised and analysed. Guidelines 
were provided to focal points for the monitoring of both substances. A joint progress 
report of the monitoring results was prepared with Europol – to be submitted to the 
Council’s HWPD at the beginning of 2002.  
 
A technical workshop with the national focal points was organised in June to strengthen 
the Reitox network’s capacity for the EWS on new synthetic drugs and to enhance 
EMCDDA coordination. The aim of the workshop was to have a technical discussion on 
the functioning of the EWS in order to contribute to improving national systems for the 
collection and analysis of information on new synthetic drugs, as well as to improving the 
cooperation and reporting/feedback systems. An EMCDDA guidance document on the 
early warning system on new synthetic drugs, which would serve as a practical booklet 
on various aspects of the EWS including guidelines for the Reitox joint action core task 
was discussed. The outcome of the workshop was subsequently adopted at the Reitox 
meeting in October.  
 
Risk assessment of the new synthetic drug PMMA (article 4 of the joint action) 
The considerations by the HWPD (under the Swedish Presidency), of the ‘EMCDDA–
Europol progress report on PMMA/PMA‘ led to its decision for a risk assessment of 
PMMA (para-methoxymethamphetamine), particularly in association with PMA (para-
methoxyamphetamine), under article 4 of the EU joint action. This risk-assessment 
exercise entailed a preparatory meeting with the Scientific Committee’s subcommittee 
on risk assessment in early October where a scientific literature review on the substance 
was presented. On 29 October 2001, a meeting was held of the Scientific Committee of 
the EMCDDA extended with experts nominated by the Member States and 
representatives of the European Commission, Europol and the EMEA to assess the 
health and social risks of PMMA alone, or when combined with PMA in ‘ecstasy’-like 
tablets, as well as the possible consequences of prohibition of PMMA. The meeting 
resulted in the formal adoption of the ‘Report on the risk assessment of PMMA in the 
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framework of the joint action on new synthetic drugs’, prepared and finalised by the 
Centre and the subcommittee on risk assessment. The opinion which received strong 
support at the meeting was that this compound should be placed under control largely 
due to the high risks of overdose associated with it, especially when associated with 
PMA in ‘ecstasy’-like tablets. 
 
The report was consequently submitted to the Belgian Presidency of the Council’s 
HWPD, to the Secretary-General of the Council and to the European Commission for 
further action in accordance with article 5 of the joint action (procedure for bringing 
specific new synthetic drugs under control). It was presented at the meeting of the 
HWPD on 20 November, and followed up with the submission of the Commission’s 
opinion to the Council on 6 December. With reference to this, the Presidency put forward 
conclusions at the HWPD meeting on 11 December calling for the drug to be subject to 
control measures. These conclusions are expected to be adopted at the beginning of 
2002 by the EU Council under the Spanish Presidency.  
 
A technical expert meeting was held on 14 September with the Scientific Committee’s 
subcommittee on risk assessment to further develop the guidelines for the risk 
assessment of new synthetic drugs. The aim of the meeting was to validate the 
mechanism for scoring and weighting the risk-assessment criteria by using MDMA as a 
possible benchmarking substance. Following a presentation of the technical annexes to 
the Guidelines which were prepared on MDMA, the subcommittee assessed the scoring 
instrument by using MDMA data. The results of this exercise were presented at the 16th 
Scientific Committee meeting, where other members of the committee were invited to 
participate in the exercise. The conclusion on whether the scoring instrument could be 
used for the purpose of further developing the guidelines will be taken next year by the 
full committee. 
 
Outputs 
Reports 
 ‘EMCDDA-Europol Progress Report on PMMA/PMA‘ in accordance with article 3 
of the joint action on new synthetic drugs of 16 June 1997 
 ‘Report on the risk assessment of PMMA in the framework of the joint action on 
new synthetic drugs’ 
 ‘Guidance document on the Early Warning System on new synthetic drugs’ 
Studies 
Rommelspacher, H., ‘Review of the pharmacotoxicological data on PMMA’ 
De la Torre, R,. Farré, M., and. Roset, P.N, ‘Review of the pharmacotoxicological 
data on MDMA for the further development of the risk-assessment methodology’ 
Henry, J.A., ‘Review of the scientific data on deaths and non-fatal hospital 
emergencies involving MDMA for the further development of the risk-assessment 
methodology’ 
Publications 
 ‘Report on the risk assessment of GHB in the framework of the joint action on 
new synthetic drugs’ 
 ‘Report on the risk assessment of ketamine in the framework of the joint action  
on new synthetic drugs’ 
For further information on the joint action see: 
http://www.emcdda.org/policy_law/joint_action.shtml 
General report of activities 2001 31
 
 
Monitoring national and Community strategies and their impact 
 
National drug strategies 
Objectives  
To describe the contents and structures of national drug strategies (Actions 
Plans), and drug-related coordination arrangements in the EU countries, in order 
to support answers to the EU action plan (2) 
To provide access to drug-related legal and policy information on EU countries in 
order to support the development of other EMCDDA projects; answers to 
Member States, media, and public; and to the EU action plan (3) 
 
Activities 
The preliminary study on ‘Drug coordination arrangements’ (778KB) was delivered to the 
European Commission services at the end of February. This was followed up with an 
intermediate report on National drug strategies and coordination arrangements delivered 
in December.  
 
On 26 June 2001, World Drugs Day, the online European Legal Database on Drugs 
(ELDD) was launched. It includes 15 country profiles, 417 texts of law, two comparative 
studies, and a comprehensive section on main trends in drug law. Guidelines and tools 
have been provided to national focal points and legal correspondents on data reporting: 
ELDD and national reports.  
 
Two external research projects were finalised: The ‘study on drugs expenditure in the 
EU’ and the ‘study on the prosecution of drug users’.  
 
Outputs 
Preliminary report on the Drug coordination arrangements (772KB) 
  ELDD http://eldd.emcdda.org 
A first inventory of national strategies  
 
 
                                                
(2) Art.1.1.7 and  Art. 1.1.2 of the EU Action Plan on drugs 2000–2004, Cordrogue 32 9283/00 
(3) Art. 1.5 of the EU Action Plan on drugs 2000–2004, Cordrogue 32 9283/00 
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EC-relevant programmes and instruments – EU action plan and benchmarking 
 
Objectives  
To obtain all relevant information on EC drug-related programmes and tools 
To set up ‘markers’ with Europol for the follow-up of EC drug-related 
programmes and tools 
 
Activities 
Activities in this area can be summed up as follows: 
 contribution to the Commission–EMCDDA draft Memorandum of Understanding, 
including participation in a coordination meeting with the drug coordination unit of 
the Commission; 
 drafting of the EMCDDA’s contribution to the Commission’s  ‘Communication on 
the implementation of the European Union action plan on drugs (2000-2004)’ 
(170KB) and in particular the EMCDDA contribution to the EU scoreboard of 
activities 2000-2001 of the plan; 
 drafting of a report on the identification of criteria for an evaluation of the EU 
strategy on drugs (2000-2004); 
management of a Reitox think tank on the evaluation of the European Union 
strategy on drugs (2000-2004); 
 production of an EMCDDA compilation system for the 1999 and 2003 snapshots 
of the EU action plan; 
 coordination of activities and follow-up of the Drug prevention programme of the 
Health and Consumer Protection Directorate of the Commission (SanCo), 
including participation as observer to the SanCo projects selection committees 
and support with the responses programme on the production of draft Council 
recommendation on the prevention and reduction of risks associated with drug 
dependence; 
 contribution to the EMCDDA 2001 Annual report; and 
 participation at two national drugs conferences and to the Institutional Committee 
for the preparation of a Drugs World Forum in 2002. 
 
Outputs 
• ‘Communication on the implementation of the European Union action plan on 
drugs (2000–2004)’ (170KB) Com (2001) 301 final of 8 June 2001 
• ‘Report by the EMCDDA and Europol on the identification of criteria for an 
evaluation of the European Union Strategy on Drugs (2000–2004) (205KB) by 
the Commission’ and annex containing the parameters (200KB) 
• Draft Memorandum of Understanding with the European Commission 
 
For further information see: 
http://www.emcdda.org/policy_law/eu.shtml 
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Reitox 
 
Overview 
During 2001, an external contractor evaluated the activities and products of the Reitox 
focal points, as well as their contribution to the EMCDDA objectives and results. It is 
expected that in its January 2002 meeting, the Management Board will take its first 
decision on the follow-up to the evaluation results (904KB). 
 
At the beginning of 2001, Reitox formally welcomed its 16th national focal point, Norway. 
 
The actions foreseen in the 2001 work programme were successfully completed. They 
principally concerned: the active participation in the external evaluation process; the co-
ordination and animation of the Reitox network; the improvement of communication 
amongst the different partners; the organisation of meetings (Heads of focal points 
meetings, “cluster” meetings and evaluation steering group meetings); the execution of 
the ‘core tasks’ contracts; the harmonisation of EMCDDA requests to focal points; and 
the quality control of the inputs from focal points and provision of feedback to them. 
Quality control and feedback mainly concerned the national reports, statistical tables, the 
joint action on new synthetic drugs and EDDRA. 
 
During 2001, the Reitox coordination team visited all focal points (with the exception of 
the Scandinavian countries which will be visited in early 2002) and ‘clustered’ them in 
groups of three to four focal points to brainstorm on two important issues: how to 
improve the general network and its interactive communication aspects and how to 
better assess and improve the quality of data and information provided by the focal 
points. In October 2001, an extensive report with the first findings of these ‘cluster 
meetings’ was drawn up and discussed with the focal points. This report, once 
completed and finalised (following the Scandinavian ‘cluster’ meeting) will form the basis 
for further discussions with all the partners involved throughout 2002. 
 
In October, within the framework of the preparation for enlargement, the candidate 
countries participated in the heads of focal points meeting for a day. 
 
A newly revised private Reitox website was also launched. This password-protected 
website was not only revised from a structurally and content-related point of view, but 
also introduces interactive communication facilities, aiming at improving an easier daily 
communication flow between the EMCDDA and its focal points. Throughout 2002, the 
website will be further improved and the members of the EMCDDA Management Board 
and Scientific Committee, as well as the Enlargement candidate countries will also 
receive full access to it. 
 
 
Reitox data and information quality and improvement 
Objectives  
To harmonise the guidelines for the 2001 national reports  
To improve completeness and comparability of data and information provided by 
the national focal points regarding the national reports 
To identify best procedures and criteria for improving the data quality in the 
framework of the Reitox core tasks 
 
Activities 
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The data quality criteria relating to Reitox core tasks were defined, including 
collaboration with the joint action in defining criteria for feedback. Work was undertaken 
to improve the quality of the scientific information contained in the national reports and 
information map. Visits and cluster meetings with the national focal points focused on 
data quality and the related organisational aspects. 
 
Outputs 
Template for national reports and information map evaluation  
Bilateral feedback on national reports 2001, including statistical tables 
Guidelines for national reports 2002 
Feedback on information map on epidemiological information sources 
 
For further information on Reitox see: 
http://www.emcdda.org/partners/reitox.shtml 
 
 
Enlargement 
 
Cooperation with candidate countries 
Objectives  
To start providing technical assistance to the candidate countries of the CEECs 
and prepare their integration in the activities of the EMCDDA 
To prepare a cooperation project with Cyprus, Malta and a follow-up to the EU 
strategy related to Turkey 
 
Activities 
CEECs 
The technical assistance project commenced 1 February 2001. A reference framework 
was drawn up and an assessment of the available national reports made. Joint 
assessment exercises were undertaken in the 10 CEECs with the assistance of Reitox 
and EU experts, and in partnership with existing twinning projects. Coordination and 
information meetings were organised and attended with the Commission and with EU 
Member States and national focal points. 
 
The first Reitox extended seminar was organised with participants from the ten CEECs 
and representatives from Bosnia and Herzegovina and FYROM, and with observers 
from Cyprus, Malta and Turkey. During this seminar, the process of building the Reitox 
national focal points and progress of their activities were reported. The guidelines for the 
national reports 2001, the five key epidemiological indicators and for drug seizures and 
drug-related arrests were presented as well as the European Legal Database on Drugs 
and the joint action on new synthetic drugs. The format for the national action plans and 
presentation of the Reitox academy training project were also discussed. 
 
Cyprus, Malta and Turkey 
Cooperation was taken up with the geographical units at DG Enlargement and an  
assessment mission in Turkey was carried out. Further assessment missions to Cyprus 
and Malta are being prepared. A detailed estimate of the impact of Enlargement on the 
work of the Centre was also drawn up.  
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Outputs 
Phare-EMCDDA project inception and quarterly progress reports 
Assessment of the national reports produced by the 10 CEECs 
 10 Assessment reports on the situation in the 10 CEECs 
 1 Preliminary Assessment Report for Turkey  
Estimate of the impact of Enlargement on the EMCDDA 
Chapter on the CEECs in the 2001 Annual report 
 10 country profiles on national drug Information system development (tool for 
monitoring), on the base of the Summary Assessment Reports 
Working documents prepared for the Management Board 
Slides and PowerPoint presentations 
CD-ROM prepared with training materials and docs presented during the Reitox 
Extended Seminar 
Start of the extension of Reitox website to the candidate countries 
 
For further information on work with the candidate countries see: 
http://www.emcdda.org/partners/ceecs.shtml 
 
  
Cooperation with EFTA countries 
Objectives  
To ensure the full integration of Norway into the EMCDDA’s activities 
 
Activities and outputs 
An official coordination meeting was organised with Norwegian authorities and the 
representative of the new national focal point. In September, a document on the 
conditions for the participation of Norway in the activities of the Centre was prepared for 
Management Board approval. Norway was also able to contribute to the 2001 Annual 
report. 
 
A working paper on conditions for the participation of Iceland in the activities of the 
Centre was prepared in close cooperation with the relevant services at DG Enlargement. 
Further activity in relation to Iceland’s application will be an assessment mission in 2002, 
if Iceland maintains its formal application for membership. 
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Communication and dissemination 
 
Offline publications 
Objectives 
To produce a printed publication, addressing the most important aspects of the 
drugs phenomenon in the EU 
To produce a printed publication reflecting the main results and achievements of 
the EMCDDA in 2000 
To publish the EMCDDA budget in the EU official journal; 
To launch a new series of targeted briefing notes for policymakers 
To produce publications in the framework of the JA on NSDs to support 
legislative action 
To consolidate and improve the EMCDDA specialised series – Monographs, 
Insights and Manuals 
To continue to produce and improve the EMCDDA bimonthly newsletter offline 
 
Activities  
The 2001 Annual report on the state of the drugs problem in the European Union was 
published in the 11 EU languages and also, for the first time, in Norwegian. This year the 
report was edited in-house.  A special effort was made to separate out the information 
on situation and trends so as to make it more accessible. An expanded online version 
was also prepared with further graphics, references and statistical tables. 
 
In 2001, the EMCDDA also published its General report of activities 2000; six issues of 
its redesigned, bimonthly newsletter, Drugnet Europe; one title in its Scientific 
Monograph series, one in its Insights series and one in its Manual series. A further two 
Risk assessment reports and an Insights are in the final stages of production. 
 
Increasingly the website is used for the dissemination of project reports and summaries 
and an extensive amount of time was spent on editing such material for online 
dissemination.  
 
Outputs 
 2001 Annual report on the state of the drugs problem in the European Union 
General report of activities 2000 
EMCDDA budget 2000 
Making the most of the EMCDDA – test policy briefing  
Drugnet Europe – six issues 
Modelling drug use: methods to quantify and understand hidden processes 
(Monograph 6) 
 Injecting drug use, risk behaviour and qualitative research in the time of AIDS 
(Insights 4) 
Guidelines for the evaluation of outreach work (Manual 2) 
 25 edited technical reports and executive summaries 
 
Details of all the EMCDDA’s publications can be found at: 
http://www.emcdda.org/infopoint/publications.shtml 
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Online publications 
Objectives 
To integrate and publish the newly developed European Legal Database on Drugs 
(ELDD) 
To integrate and improve the Reitox site including developing special areas with 
specific access rights 
To further develop the public website 
To migrate the Qualitative European Drug Research (QED) network’s website to the 
EMCDDA interface 
To develop online analytical briefings an online statistical bulletin and prototype for 
DrugNet online 
To further develop www.fad.phare.org 
 
Activities 
In 2001, the public website (http://www.emcdda.org) was restructured to change the 
focus from institutional towards drugs-related content. The concept of setting up 
dedicated websites for specific products was also developed.  
 
The development of the online analytical briefings, online statistical bulletin and Drugnet 
online was postponed due to the rescheduling of the offline versions. However, instead 
the 2001 Annual report online was set up as a dedicated website in four languages, 
thereby improving the multilingual aspect of the EMCDDA’s online publications. 
 
On a more technical level, a new search interface was developed for several of the 
Centre’s websites and a registration service allowing the interested audience to receive 
e-mail alerts for news releases, the release of new publications and reports, and general 
EMCDDA news was introduced. The process for updating the different websites was 
enhanced through the provision of a content management application tool. This enables 
several users to simultaneously update Home pages without having to access the actual 
HTML page. 
 
The design and set up of ELDD was finalised and the new product launched in June. 
The QED website http://www.qed.org.uk was migrated to the EMCDDA technical 
environment and a guestbook facility was provided. The Reitox website was redesigned 
and now includes the possibility of dedicated areas for the Management Board, Scientific 
Committee, or for easy integration of the CEECs/Phare countries.  
 
Outputs 
Newly structured website http://www.emcdda.org 
European Legal Database on Drugs http://eldd.emcdda.org/ 
New QED website http://qed.emcdda.org/ 
Content Management Application: http://cma.emcdda.org 
New Reitox Website: http://w3.reitox.emcdda.org 
New Intranet (only accessible within the EMCDDA) http://intra.emcdda.org 
Annual report online website: http://annualreport.emcdda.org 
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Media relations 
The EMCDDA’s media relations programme is built along three axes: 1) the distillation 
and proactive dissemination of news stories and quality information to the media; 2) 
interaction with the media and the provision of appropriate response services; 3) impact-
assessment through follow-up and the preparation of press reviews. The overall goal of 
the programme is to raise the visibility of the Centre as the European authority in the 
drugs field. Tasks and activities in 2001 were conceived in line with the EMCDDA 
Dissemination and Communication Strategy and Action Plan, which regard the media as 
an important conduit of information from the EMCDDA to policy-makers and the general 
public.  
 
Objectives  
To prepare media-friendly information 
To promote/marketing products via the media 
To launch new products 
To expand horizons (thematically and geographically) 
To increase the EMCDDA’s presence on national press websites 
To establish a regular e-mail service for a core group of drug-specialised key 
journalists 
To launch the Annual report on the state of the drugs problem in the European 
Union 
To prepare press reviews and monitoring (follow-up of press actions)  
 
Activities 
In 2001, the EMCDDA boosted its dissemination of news stories to the media, producing 
a total of 16 news releases during the year. These focused on new EMCDDA product 
launches and key visits/events. The Centre also launched a series of quarterly online 
feature articles complementing selected releases. These are designed as downloadable 
ready-made pieces for use by magazines and journals. In January 2001, a new-look 
Drugnet Europe was launched and promoted to journalists. The newsletter places 
greater emphasis on the results of studies, special features and product promotions and 
is regularly used by journalists as a background source.  
 
Improving services for journalists was a priority in 2001. On 26 June, in the context of a 
promotional event for International Day Against Drug Abuse and Illicit Drug Trafficking 
(see Marketing), the EMCDDA launched a News and media services section on its 
website specially created for journalists from the print and broadcast media worldwide. 
Among others, this new product offers instant access to news releases; feature articles; 
Drugnet Europe; photographs; and a registration facility for automatic news alerts. In 
parallel, the EMCDDA’s media helpdesk provided the daily service of responding to 
journalists’ requests.  
 
The Centre expanded its media contacts in 2001 to the youth media, on the previous 
recommendation of an expert consultant to step up contacts with specialised media. A 
news release on on-site pill testing in the EU was targeted at this group in October 
increasing the Centre’s visibility among this group. In the run-up to the launch of the 
Annual report 2001, the Centre increased its media contacts in Norway, the CEECs and 
the US and updated existing contacts in the 15 EU Member States. Contacts were also 
established with the editors of online versions of newspapers throughout the EU as a 
first step to increase the EMCDDA’s presence on national press websites. An EMCDDA 
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core group of drug-specialised journalists was expanded in 2001 and regular e-mail 
contact was maintained with the group.  
 
The EMCDDA hosted journalist delegations in the context of the visits of the Presidents 
of Chile and Argentina in September and November. It also held a news conference in 
Brussels on 19 November on the signing of a Memorandum of Understanding between 
the EMCDDA and Europol. A ‘Media day’ was organised on 20 November launching the 
2001 Annual report. This consisted of a European launch of the report to the media at a 
news conference at the European Parliament (Brussels); presentations to a core group 
of drug-specialised journalists; and the intensive dissemination of report’s findings 
throughout the EU and further a field. Four news releases in 12 languages were 
disseminated by fax, e-mail, mailings and a dedicated website 2001 Annual report online 
(see Online publications). 
 
The Centre produced quarterly press reviews in 2001 to measure the impact of its 
interaction with the media. An Annual report press review of over 400 pages was 
prepared in the wake of the launch.  
 
Outputs 
 16 news releases  
 4 feature articles  
New-look Drugnet Europe (6 editions in DE, EN, FR, PT). 
Quarterly special feature articles (launched March); a News and media services 
section of the website (launched June). 
Contacts were expanded in youth media, Norway, CEECs, US. 
Expansion of core group of drug-specialised journalists, regular e-mail contact    
  ‘Media day’, 20 November 
Quarterly press reviews; Annual report press review  
 
For further information on EMCDDA media relations see:  
http://www.emcdda.org/infopoint/news_media.shtml 
  
 
Interface with MS audiences 
Objectives  
To satisfy the needs of the Centre’s primary audiences by providing them with 
high-quality and tailored information (on time and, whenever possible, in their 
own national language) on request  
To further improve the image that the national authorities have of the Centre – in 
particular, national parliaments and governments – by providing them with a 
comprehensive overview of the drug situation and all the relevant information 
they might need when visiting the Centre and when being visited by 
representatives of the EMCDDA 
To meet the real estate needs of the Centre’s within reasonable delays  
To ensure the full implementation of the Protocol signed between Portugal and 
the EMCDDA 
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Activities 
The feasibility of creating a mechanism to rapidly provide policy-makers with tailored 
information on drugs on request was explored as well as the possibility of creating a core 
group of policy-makers to review the Centre’s outputs. Contacts with Embassies were 
taken up within the framework of the visits to the Centre of the respective Heads of State. 
There were also regular contacts with the Portuguese authorities, mainly through the 
IPDT, but also with the Presidency of the Council of Ministers, the Ministry of the Foreign 
Affairs and several municipalities, regarding the implementation of the Protocol between 
the Government and the Centre, the building issue, the visits of members of the 
Government to the Centre, the preparation of a stand for the 26 June event and other 
bilateral issues.  
 
Thorough market research was carried out regarding buildings to rent or buy. There were 
regular contacts with several real estate agencies and building owners and a working 
group was set up with the Portuguese authorities to assess the different offers.  
 
Outputs 
Proposal for a mechanism to provide the policy-makers with tailored information on 
drugs 
Proposal on the creation of a core group of policy-makers 
 Letters, meetings, phone calls, etc., and all other means to pursue or establish a 
dialogue with the Portuguese government and administration 
Briefings on the buildings available for purchase or rent and several supporting 
documents to help and back the decisions to be taken by the EMCDDA bodies 
Co-preparation of the visits to the Centre of the Presidents of Chile and Argentina 
 
 
Communication and dissemination-related activities 
In 2001, activities in this area were divided into five groups: 1) corporate identity; 2) 
multilingual output; 3) distribution; 4) marketing; and 5) editing. All five activities relate to 
the vision and objectives of the EMCDDA’s Dissemination and Communication Strategy 
and Action Plan. Together they aim to improve the visual, textual and linguistic quality of 
the Centre’s products (1, 2, 5) and to ensure that they reach the target groups for which 
they are intended (3, 4). 
 
Objectives 
To compile an EMCDDA corporate identity manual and CD-ROM  
To increase multilingualism in EMCDDA online and offline outputs and establish a 
terminological database 
To ensure distribution of EMCDDA products to the various target audiences and to 
examine and implement optimal distribution channels for EMCDDA products  
To define a strategy for marketing/promotions to raise the visibility of the EMCDDA 
To strengthen the editorial capacity and standards of the Centre 
 
Activities 
An EMCDDA corporate-identity working group was set up in March to discuss the 
agency’s visual communication history and its scope for development. A call for tender 
was launched in May and a kick-off meeting held with the selected contractor in 
September. The scheduled completion date for the project (Manual and CD-ROM) is June 
2002. From September–December 2001, work centred on the first phase of the project: 
the development of the EMCDDA logo. 
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In line with the user-focused Dissemination and Communication Strategy, which calls for a 
greater multilingual output, the EMCDDA increased its linguistic coverage in 2001 in both 
its online and offline products. Selected information was offered in 12 languages on the 
EMCDDA homepage and a dedicated website 2001 Annual report online was developed in 
four languages (see Online publications). For the first time, the printed Annual report was 
produced in 12 languages – 11 EU plus Norwegian – following adhesion of Norway to the 
EMCDDA in January 2001. Preparations were also made for the launch of a new series of 
policy briefings in 2002 in 12 languages and a new Spanish version of Drugnet Europe. A 
project/working group to monitor terminology in EMCDDA publications (focusing initially on 
French and Portuguese) was set up in 2001, and training was provided for the 
development of a terminological database during 2002.  
 
In line with the above-mentioned strategy and the need to better target EMCDDA products, 
the Centre created a number of newly tailored mailing lists in 2001. These covered Latin 
America and national policy-makers in the EU in preparation for the launch of a new series 
of policy briefings in 2002. A discussion paper for Joint EMCDDA-Reitox dissemination 
activities was presented to the Reitox meeting in October and modus operandi will be 
established in 2002.  
 
A marketing/promotions strategy to raise the EMCDDA’s visibility was presented to the 
Bureau in April. This centred on three annual events: an EMCDDA annual conference; an 
event marking International Day Against Drug Abuse and Illicit Drug Trafficking (26 June); 
and the European launch of the EMCDDA Annual report (see Media relations). As a result, 
on 26 June, the EMCDDA hosted a promotional stand in Lisbon at a ‘Prevention village’, 
organised by the Portuguese Focal Point, where it launched its new European Legal 
Database on Drugs (ELDD) in the context of its newly structured website. It also attended 
Online Information 2001 in London in December where it presented its website and 
dedicated site 2001 Annual report online. The design of a new series of marketing 
products was commissioned under the corporate identity project and will be produced in 
2002. Six marketing mailings to promote new EMCDDA products were launched to the 
book reviewers of over 80, through EMCDDA staff on mission and through contributions to 
external directories and journals. A test policy briefing promoting the Centre’s work 
programme was released in September.  
 
Responding to user-focus of the strategy and the need to provide specific groups with 
products in an appropriate language, efforts were made in 2001 to contract editors with 
specific writing skills (scientific and medical editors, policy writer, etc). An EMCDDA 
editorial group was also set up in 2001 and developed norms and guidelines for EMCDDA 
publications.  
 
Outputs 
Establishment of corporate-identity group and launch of project 
Establishment of terminology group; groundwork in FR and PT; increased 
multilingual output 
Targeted mailing lists; discussion paper on EMCDDA–Reitox joint dissemination 
activities 
Making the most of the EMCDDA briefing paper; document on three EMCDDA 
annual events 
Guidelines – EMCDDA editorial group 
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Documentation 
Objectives 
To contribute to providing a high-quality documentary service on drugs, drug 
addiction and their consequences 
To provide users (internal and external) with a qualitative tool to access the 
EMCDDA library collection through Bibliodatabase 
To contribute to the successful completion of in-house research projects 
To reinforce network activities in the documentary field with national, European and 
international partners 
 
Activities and outputs 
Internally, work has concentrated on the progressive consolidation of the performance of 
the documentation system which contributes to the successful completion of research 
projects. Internal work included carrying out a users survey to determine the profile of the 
services required following the reform. These questionnaires were evaluated and print and 
electronic material selected accordingly. 
 
The bibliographic database underwent rigorous quality control and a fully operational    
EMCDDA online catalogue was developed with retrospective and current indexing in the 
following thematic areas: ‘Epidemiology ‘, ‘Demand reduction’, ‘Drug and related 
perspectives’, ‘Drug policies’, ‘European Union’ and ‘Health and generalities’. 
  
The documentation service provided assistance through the acquisition of specialised 
articles, bibliographic retrieval on internal and external databases and CD-ROMS and 
operated its internal dissemination of information by profile policy. A press clipping service 
covering the main EMCDDA working domains (legislation, new trends, policies, 
prevention, etc.) was piloted.  
 
The team also made a contribution to the terminology project: selecting and collecting the 
relevant terms in the Portuguese version and following-up the list of key words used for 
indexing and retrieval in the documentation area. An increasing number of information and 
documentation requests are received and processed. Arrangements have been set up with 
European and international institutions for the exchange of publications. 
 
Externally, the aim is to provide a high-quality information service, disseminating products 
(databases and replies for information requests) and participating in European and 
international projects. The EMCDDA is member of ELISAD, EUROLIB and partner in the 
international project of Virtual  Clearinghouse (coordinated by the Canadian Centre of 
Substance Abuse) and participated in meetings (17th Assemblée Générale EUROLIB, 
Varsovie, 9 May-11, Virtual Clearinghouse on Alcohol, Tobacco and Other Drugs, 
Vancouver, 30 April-2 May) and collaborated in partnership committees, online technical 
discussions and common projects.  
 
For further information on EMCDDA documentation activities see: 
http://oxford.emcdda.org/winlib/index.html 
http://www.emcdda.org/infopoint/library_resources/virtlib.shtml 
http://www.emcdda.org/infopoint/library_resources/serials.shtml 
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II – Supporting activities 
 
Administrative support 
 
Overview of main achievements 
Attention focused on the implementation of the relevant measures of the EMCDDA reform 
plan adopted in September 2000. This entailed in particular: 
 
 the setting up of instruments and procedures for planning, monitoring, 
implementing and reporting the work of the EMCDDA and the allocation/use of its 
resources, in accordance with the activity-based management and project-based 
working methods adopted by the Centre; 
 the implementation of the EMCDDA strategy for human resources, through the 
adoption of a new organisational chart, reflecting the project-based structure of the 
EMCDDA work programme; the job description for each post; the definition and 
implementation of a training programme for the staff of the Centre; and 
 the assessment of the EMCDDA present and expected needs in terms of real 
estate infrastructure and the solutions available to cope with the inadequacy of the 
working space provided by the current premises of the Centre in Lisbon. 
 
 
Human and material resources 
Objectives  
To implement the internal reform process in the area of human resources, to 
ensure the daily management of human resources and to commence 
implementation of the EMCDDA’s human resources policy as adopted by the 
Management Board at its meeting of 10-12 January 2001 
To ensure the daily management of the material resources 
 
Activities and outputs 
The activities and outputs have been threefold. Firstly, the focus has been on the 
implementation of the internal reform process in the field of human resources by 
establishing a job description of each post and a definition of functions and powers 
associated with each standard position (the organigramme and function list are presented 
in annex).  Secondly, there has been the effective daily management of the human 
resources. Thirdly, the gradual implementation of some parts of the EMCDDA’s human 
resources policy has got underway. The Commission decision of 1983 on grading and on 
recruitment has been transposed; training, social and equal opportunities policies have 
been set up; an assessment and promotion exercise has been launched; a procedure for 
transforming temporary posts into permanent posts has been worked out and general 
provisions for implementing the staff regulations have been adopted as well as the powers 
of the appointing authority (AIPN) and authority empowered to conclude contracts of 
employment (AHCC) organised. 
 
In the area of material resources, the effective daily management of the EMCDDA’s 
material resources has been assured. 
 
 
Financial and accounting management  
In 2001, key financial decisions taken by the EMCDDA Management Board included: 
• a decision to offer the Director discharge on the implementation of the 1999 budget; 
• the adoption of the 2001 budget of EUR 10 204 889; 
the adoption of the EMCDDA’s 2002 preliminary draft budget of EUR  10 356 361. 
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The budgetary figures for 2001 are presented in the tables below.  
 
 Budgetary provisions and appropriations, 2001 
 
Title Description EUR 
 
1. 
 
Expenditure relating to persons working with the office   
 
 • Staff in active employment 4 740 000
 
 
• Other staff-related expenditure (exchange of officials, etc.) 40 000
   
    Total under Title 1 4 780 000
  
2. Buildings, equipment and sundry operating expenditure  
 
 • Investment in immovable property, rental of buildings and 
associated costs 
350 000
 • Data processing 394 250
 • Movable property and associated costs 193 000
 • Current administrative expenditure+ Postal charges and 
telecommunications 
196 500
 • Socio-medical infrastructure 40 000
  
  Total under Title 2 1 173 750
  
3. Expenditure resulting from special functions carried out by the 
institution 
 
 • Statutory meetings 308 000
 • Expenditure on formal and others meetings +Representative 
expenses 
156 000
 • Studies, surveys, consultations  220 000
 • Publishing 762 500
 • European Network on Drugs and Drug Addiction Reitox 1 500 000
 • Missions 248 500
  
  Total under Title 3 3 195 000
  
 Total core budget 9 148 750
   
4. Expenditure relating to other subsidies 
• EC financing of specific projects  
• PHARE financing for implementing pre-accession strategy 
 
 
p.m.
1 056 139
10. Other expenses (reserve) 
 
0
 Total budget 10 204  889
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Execution of the budget: Credit consumption, 2001 
(Commitments) 
 
Title Description % consumption of 
available credits 
1. Staff  
Staff salaries, allowances, etc. 
 
 
97,50% 
 
2. Buildings, equipment and sundry operating 
expenditure 
 
 
97,92% 
3. Operating expenditure 
 
96,10% 
 
4. Expenditure relating to other subsidies 0% 
   
  Total consumption (Titles 1, 2, 3 ) 97,05% 
 
EMCDDA balance sheet for the financial years 2000 and 1999: Assets 
  
Assets 2000 1999 
Fixed assets  
• Fixed assets 3 827 537.75 3 603 235.96 
Subtotal 3 827 537.75 3 603 235.96 
Stocks  
• Office equipment 11 725.96 16 910.50 
Subtotal 11 725.96 16 910.50 
Current assets  
• Commission subsidy 36 350.00 0 
• Specific grants 100 684.82 265 005.15 
• VAT to be recovered  3 026.03 3 352.24 
• Sundry debtors 43 465.28 36 177.67 
• Payments on specific 
subsidies  1 318.24
 
1 318.24 
Subtotal 184 844.37 305 853.30 
Cash accounts  
• Bank 4 372 401.77 4 276 232.96 
• Imprest account 4 000.00 48 935.51 
• Transfers in progress -19 776.95 
Subtotal 4 376 401.77 4 305 391.52 
  
Total assets 8 400 509.85 8 231 391.38 
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 EMCDDA balance sheet for the financial years 1999 and 1998: Liabilities 
 Liabilities 2000 1999 
   
 Fixed capital  
 • Own capital 3 839 263.71 3 620 146.46 
 • Balance for the 
financial year  
2 075 607.24 1 616 809.14 
 Subtotal 5 914 870.95 5 236 955.60 
   
 Current liabilities  
 • Commission 
subsidy 
36 350.00 0 
 • Specific grants 100 684.82 265 005.15 
 • VAT to be 
recovered  
3 026.03 3 352.24 
 • Sundry creditors 38 954.02 150 604.24 
 • Automatic carry-
overs of 
appropriations  
1 960 301.05 2 132 831.28 
 • Non-automatic 
carry-overs of 
appropriations 
233 579.98 279 564.00 
 • Re-use accounts 112 743.00 163 078.77 
 Subtotal 2 485 638.90 2 994 435.68 
   
 Total liabilities 8 400 509.85 8 231 391.38 
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Out-turn account 
Revenue and expenditure for the financial years 2000 and 1999  
 
2000 1999 
Revenue 
• EC subsidy 8 213 650.00 8 155 781.24 
• Miscellaneous revenue 0 0 
Total revenue 8 213 650.00 8 155 781.24
 
Expenditure  
• Title I: Staff expenditure 
– Payments 3 875 935.14 3 367 394.50 
– Automatic carry-overs of appropriations 112 433.87 59 178.13 
         – Non-automatic carry-overs of appropriations 13 569.09 204 674.00
• Title II: Buildings, equipment and miscellaneous 
administrative expenditure 
– Payments 681 771.48 636 819.29 
– Automatic carry-overs of appropriations 339 659.43 240 976.52 
– Non-automatic carry-overs of appropriations 76 630.99 0
 
• Title III: Operating expenditure  
– Payments 1 498 412.35 1 568 872.88 
– Automatic carry-overs of appropriations 1 508 207.75 1 832 676.63 
– Non-automatic carry-overs of appropriations 143 379.90 74 890.00 
Total expenditure 8 250 000.00 7 985 481.95 
Out-turn for the financial year   
• Budgetary out-turn -36 350.00 170 299.29 
• Cancelled appropriations 495 148.10 159 816.53 
• Balance carried over from the previous year 1 616 809.14 1 286 693.32
  
Balance for the financial year 2 075 607.24 1 616 809.14 
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Planning and evaluation 
Objectives  
To implement the project-based planning, monitoring and reporting in accordance 
with the methods for activity-based management/budgeting (ABM/ABB) adopted by 
the EMCDDA (pilot phase)  
To provide in-house assistance and advice with regard to the legal aspects of the 
implementation of the EMCDDA activities and its functioning  
 
Activities and outputs 
The EMCDDA instruments and procedures for planning, monitoring, reporting and 
assessing the work of the Centre have been revised, in accordance with the project-based 
working methods and the ABM/ABB principles adopted. The procedures for the 
implementation of the EMCDDA work programme and budget were also revised in this 
light. The EMCDDA procurement policy has been assessed, to identify needs and options 
for improvement.  
 
The EMCDDA work programmes 2001–2003 and 2001, executive projects 2001, budget 
2001 (43KB) (published in the EU OJ), draft work programme 2002, draft budget 2002, 
preliminary draft budget 2003 were drawn up. A new set of project-based internal rules 
and procedures for the setting up and the implementation of the EMCDDA work 
programme and budget were devised. New project-based instruments and procedures for 
periodical reporting, including a new structure for the General report of activities which 
complies with the structure of the EMCDDA work programme were also introduced. 
 
 
Information technology 
 
Overview of main achievements 
At the beginning of 2001, the EMCDDA’s IT section became a department and a head of 
department was recruited and took up office in early November. 
 
All actions, foreseen in the work programme were successfully completed apart from the 
‘Internet firewall security audit’ action which had to be postponed until the arrival of the 
replacement of the ‘Internet security specialist’ official who left the EMCDDA in April. 
 
The main achievements of the different IT activities concerned the acquisition of IT 
infrastructure and services (e.g. PCs, servers, maintenance contracts, Internet access, a 
wide range of software), the provision of IT advice to the different scientific and 
administrative projects of the Centre, as well as the day-to-day, smooth running of the 
EMCDDA’s IT infrastructure and services.  
 
In addition, a new and comprehensive IT strategy was developed by a working group 
(composed of staff of the EMCDDA as well as representatives of some EMCDDA 
partners). During 2002, the strategy adopted will be translated and implemented into a 
concrete action plan. 
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IT basic services and infrastructures 
Objectives  
To ensure a very high level of reliability and functionality of the IT information 
technology infrastructure and its services, including daily maintenance works 
To ensure a high-quality level of technical assistance to users via the IT Call 
Centre 
To gradually replace obsolete equipment and software as well as to renew 
maintenance contracts  
To acquire equipment (PCs, printers, servers, laptops, network devices), software 
and services (e.g. access to the Internet, maintenance contracts) for new users 
and new duly justified requirements 
To link all elements (hardware and software) of the system and ensure the 
compatibility and coherent integration in the whole IT environment 
To conceptualise and implement the technical aspects of system integration 
 
Activities and outputs 
The main activities comprised of conceptualising and implementing the various 
infrastructure subsystems of the IT environment. This involved acquiring/upgrading, 
configuring and installing hardware, software and services. A Windows 2000 database 
server was installed and  maintenance contracts established for NT and Solaris servers 
and for the high availability Internet security (Firewall) system computers. The IT call 
centre provided assistance to users. Systems administration training was undertaken and 
planning for the continuous evolution and monitoring of the system took place. 
 
Administrative databases (Adonis, Teleponto, ELS, WinLib) 
Objectives  
To ensure a high level of reliability for the equipment and software used by these 
databases, including their daily maintenance 
To gradually replace obsolete equipment (e.g. the database servers) and upgrade 
to more recent software versions (e.g. Oracle), as well as to renew maintenance 
contracts  
To expand the capacity of the current database servers to cope with a more 
intensive use of these databases 
To acquire new equipment (e.g. more database servers), software (e.g. more 
Oracle licenses; upgrade to new versions of Oracle) and services (e.g. 
maintenance contract with Oracle and the database servers) for new users and 
new duly justified requirements 
To provide ongoing advice to project managers, particularly to ensure the 
coherence and full functionality of the databases in the EMCDDA’s IT environment  
To conceptualise and implement the technical aspects of system integration 
 
Activities and outputs 
Advice was provided to project managers on the status and evolution of Adonis (Mail 
workflow), Teleponto (Time Schedule system) and ELS (Inventory system) and the ELS 
system was fully implemented. System administration and maintenance contracts were 
awarded and training in the administration of these databases undertaken. 
  
SI2 system 
Objectives  
To ensure a very high level of reliability for the equipment and software used by 
SI–2, including their daily maintenance works 
To gradually replace poor-performing equipment (e.g. the SI–2 server), upgrade 
software and renew maintenance contracts 
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To renew the annual development and technical support contract in the context of 
the inter-Agencies ‘Common Support Service’ (including the installation of the new 
versions at the EMCDDA)  
To provide advice on an ongoing basis to project managers, particularly to ensure 
the coherence and full functionality of the SI2 system in the EMCDDA’s IT 
environment 
To implement the technical aspects of system integration 
 
Activities and outputs 
Maintenance contracts were set up for the different parts of the SI2 system and the 
training of the new system administrator for SI2 undertaken. Daily system administration 
tasks carried out included: troubleshooting, monitoring, users assistance, etc. The 
evolution of the SI2 system – to be partly located at the Commission’s data centre – was 
planned. Maintenance contracts for the Oracle software licenses, for Business Objects and 
for the Compaq SI2 database server were set up. 
 
Electronic dissemination systems and IT advice projects 
Objectives  
• To provide advice to the project managers of the different information systems  
• To ensure technical stability of the electronic dissemination services: web servers, 
application servers, mail and news servers, directory services and related 
hardware 
• To assure technical development and upgrades of the aforementioned services in 
order to improve the overall quality 
• To better integrate the services offered 
 
Activities 
Ongoing advice was provided to project managers on the different information systems 
and databases of the EMCDDA and on the technical aspects of the development and 
exploitation of these systems according to the 2001 work programme and the common IT 
strategy. 
 
Nine Solaris machines and two NT servers used within the Electronic dissemination 
project were maintained. A new Solaris server to host websites, database systems and 
Coldfusion application server were installed. The new software (ColdFusion) was set up as 
the foundation for future online database projects and to facilitate the integration of 
interactive features. 
 
The Content Management Application developed for the websites http://www.emcdda.org, 
QED and the Reitox website was enhanced and also developed for the Intranet. A new 
search technology was implemented and virtual servers set up. A second (mirror) physical 
website was used and a shared in-house agenda introduced. 
 
Outputs 
New server Cambridge, with web services, DBMS and ColdFusion Server 
Dedicated websites, e.g. at http://eldd.emcdda.org 
 Improvement and better integration of http://emcdda.kpnqwest.pt as the mirror site 
of the Annual Report 
Common agenda at http://calendar.emcdda.org  
For project advice output, see the Online publications project 
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III – Management activities 
 
Statutory bodies and executive management 
 
Management Board 
Activities and main decisions 
At the21st meeting of the Management Board in Lisbon on 10 to 12 January, Mr. Mike 
Trace, deputy UK Anti-Drugs Coordinator, was elected new Chairman of the EMCDDA 
and Mr. Marcel Reimen, first government advisor at the Permanent Representation of 
Luxembourg to the EU, was re-elected Vice-Chairman of the Board. The Management 
Board also adopted among others: the 2001 work programme, the 2001-2003 work 
programme; the General report of activities 2000, a budget of EUR 9.148 million for 
2001; a preliminary draft budget of EUR 9.556 million for 2002; a human resources 
policy; a communication and dissemination strategy; the terms of reference for the 
external evaluation of the national focal points; and the Memorandum of Understanding 
with Interpol. The Board also gave discharge to the Director for the implementation of 
the 1999 budget.  
 
At its 22nd meeting of 5-7 September, the Management Board adopted the technical 
tools and guidelines designed by the EMCDDA to collect standardised and reliable 
information on its five key epidemiological indicators. The Board examined the progress, 
obstacles and legal framework for implementing the indicators as well as the operational 
implications for the centre. Annual reporting by Member States to the Untied Nations 
Internal Drug Control Programme (UNDCP) was also discussed. The Management 
Board was informed of the decisions of the Bureau (e.g. impact of enlargement, 
application of Iceland and Slovenia to the EMCDDA) and of general issues including the 
execution of the 2001 work programme, the 2001 Annual report, the Reitox evaluation, 
TSER network, the European Legal Database on Drugs, a feasibility study on an 
Internet-based database for drugs-related research in the EU and the template of the EU 
Action Plan 1999 snapshot.  
 
 
Bureau 
Activities and main decisions 
In 2001, the Bureau met three times in Lisbon, once in Brussels and once in London (4). 
 
At its meeting of 10 January 2001, the Bureau prepared the meeting of the Management 
Board of 10-12 January.  
 
At its meeting of 14 February, the Bureau adopted a series of action plans for the 
implementation of the 2001-2003 work programme; the 2001 work programme; the 
human resources strategy, and the dissemination and communication strategy. In 
adopting these action plans, the Bureau gave the green light to the array of projects to 
be carried out in 2001 (including the related financial and human resources). The Bureau 
also decided to address a letter to the 15 EU Member States requesting information on 
problems encountered in harmonising the EMCDDA’s five key epidemiological 
indicators. It took further note of a working paper related to budgetary matters and the 
                                                
(4) 10 January (Lisbon), 14 February (Lisbon), 20 April (Brussels), 5 September (Lisbon) and 28 November (London). 
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assessment of the impact of conclusions from the Council of the EU on information 
networking on emerging drug trends. 
 
At its meeting of 20 April, the Bureau discussed an ambitious proposal for three annual 
EMCDDA events for the coming years (International Day against Drug Abuse and Illicit 
Drug Trafficking; an annual high level EMCDDA conference and the launch of the 
Centre’s Annual report). Also discussed were the EMCDDA marketing approaches and a 
recently launched corporate identity project. Finally, issues including the implementation 
of the 2001 work programme, the budget, the terms of reference of the Scientific 
Committee, the ongoing external evaluation of the Reitox focal points, the UNDCP’s 
reporting mechanisms and a study on drug coordination mechanisms in the EU Member 
States were examined.  
 
Besides preparing the Management Board meeting of 5-7 September, the Bureau 
discussed in-depth at its meeting on 5 September the estimation of the impact of 
enlargement for the EMCDDA and the estimation of the real estate needs. It took note of 
the Iceland and Slovenia application for participation. It agreed on the publication of the 
first issue of the policy briefing series proposed for 2002 and it requested from the 
EMCDDA a precise report on the 2002 conference. The Bureau approved a transfer 
from chapter to chapter.    
 
The meeting of 28 November was given to preparing the January Management Board 
meeting.  
 
 
Scientific Committee 
Activities, main discussion points and results  
The Scientific Committee’s mandate was renewed in January 2001 for a period of three 
years. In 2001, the Scientific Committee met three times in Lisbon, holding two regular 
meetings and one extended meeting in the framework of the joint action on new 
synthetic drugs. Its subcommittee on risk assessment held two meetings. 
 
Scientific Committee meetings 
15th meeting (6 April) 
In the 15th meeting (April), the new Chairperson, Prof. Salme Ahlström (Finland), and 
Vice-Chairperson, Dr. Jean-Pol Tassin (France), were elected for the next three-year 
term.  
 
The terms of reference for the work of the committee for the period 2001–2003 (in the 
light of the EMCDDA’s work programme and reform process) were discussed and 
adopted. The Committee stated that it would continue to advocate, monitor and advise 
upon the scientific methods used by the Centre and on its scientific output. Among its 
specific tasks will be to: guarantee evaluation criteria; assure the scientific quality of the 
Centre’s Annual report; and develop its expertise and work on new synthetic drugs. 
 
Following this meeting and for the purpose of assisting the EMCDDA in guaranteeing the 
scientific quality of the Centre’s Annual Report, the committee commented on the 2001 
draft Annual Report. Comments were also delivered on the EMCDDA’s template for the 
evaluation of the 2001 national reports. 
 
Enlarged Scientific Committee Meeting (29 October) 
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The meeting on the risk assessment of the new synthetic drug PMMA (para-
methoxymethamphetamine) took place involving Scientific Committee members, 
additional experts from the Member States, representatives of the European 
Commission, Europol and the European Agency for the Evaluation of Medicinal Products 
(EMEA). The enlarged committee’s tasks were to assess the health and social risks and 
possible consequences of prohibition of the substance. The meeting resulted in the 
formal adoption of the risk-assessment report on PMMA. The report was submitted the 
following day to the Council of the EU and the European Commission for further action in 
accordance with article 5 of the joint action. 
 
16th Scientific Committee Meeting (22-23 November) 
The work plan (operational activity plan which is based on the terms of reference) for the 
committee for the period 2001-2003 was discussed and adopted. 
 
The thematic subcommittees were reconstituted. These subcommittees are aligned with 
each EMCDDA operational programme and aim to assist the Centre in implementing its 
work programme.  
 
A discussion on the EMCDDA’s 2002 draft work programme took place and an opinion 
adopted on it. The committee also put forward proposals on drug-related research 
priorities in the next EU framework research programme (2002-2006). 
 
Other items discussed at the meeting were: the guidelines of the Centre’s five key 
epidemiological indicators; the availability of treatment facilities in the EU; and, the report 
by the EMCDDA and Europol on the identification of criteria for an evaluation of the 
2000-2004 EU strategy on drugs by the European Commission (snapshot). The 
committee also took note of the main findings of the external evaluation of the Reitox 
national focal points. 
 
Subcommittee on risk assessment meetings 
On 14 September, a technical expert meeting was held on the further development of 
the Guidelines for the risk assessment of new synthetic drugs. The meeting attended by 
experts and members of the subcommittee on risk assessment commented on the 
technical annexes to the Guidelines on MDMA. Discussions centred thereafter on 
validating the mechanism for the weighting and scoring of the risk-assessment criteria by 
using MDMA as a possible benchmarking substance.  
 
On 8 October, a preparatory meeting on the pharmacotoxicology of PMMA was attended 
by members of the subcommittee. A scientific literature review on the substance was 
also presented. 
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Internal coordination, communication and quality management 
 
Internal Management Coordination Committee 
Attention was focused on the implementation and follow-up of the relevant measures of 
the EMCDDA reform plan adopted in September 2000. This entailed the setting up of an 
Internal Management Coordination Committee (IMCC). This committee assists the 
Director in preparing and monitoring the implementation of the work programmes, 
ensuring the coordination of the different teams and global coherence of the work of the 
Centre. In this context it aims particularly at ensuring regular information exchange 
flows, improving the decision-making process, ensuring timely and high quality 
production and promoting the evaluation of internal performance. All EMCDDA 
operational programmes and support activities are represented in the committee, as well 
as the executive management, the planning activities and quality management. The 
work of the Committee is organised and animated by a member of staff, the coordination 
manager, who is responsible for the internal coordination of the activities of the 
EMCDDA.   
 
In accordance with its objective to ensure a coherent, timely and highly qualitative 
progress in the implementation of the work programmes, during 2001 the activities of the 
IMCC focused on coordination issues relating to: 
 
 the setting up of the EMCDDA instruments and procedures for planning, 
monitoring, reporting and assessing the work of the Centre, in accordance with 
the project-based working methods and the ABM/ABB principles; 
 the preparation of the EMCDDA work programme for 2002; 
 the setting up of the training programme for EMCDDA staff; and 
 the development of the EMCDDA mechanisms for internal communication with 
special attention to the IT-based tools. 
 
Internal communication 
Objectives 
To satisfy the needs of the staff of the EMCDDA enhancing all the internal 
communication tools and to support and help the staff of the EMCDDA with their 
external presentations. 
 
Activities 
Two of the most important internal communication tools – the Intranet site and the home-
shared drives – were restructured. The modifications done aim to increase transparency, 
retrieval speed and clarity and to reduce information noise. The new general shared 
drive (P) was created and in operation from May and its efficiency and usefulness is 
regularly assessed. The Intranet was fully restructured and redesigned and finally 
implemented from October. Graphic presentations of data (maps, charts, tables) to 
support other projects and objectives were developed. 
 
Quality management 
Objectives  
The EMCDDA sets out five objectives along the way to total quality: 
 user satisfaction; 
 product quality; 
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 development of the Reitox network; 
 staff satisfaction; and 
 in-house productivity. 
 
The Quality Management policy will offer everyone – management and staff, at their 
individual levels of responsibility – a series of tools to enable them to achieve these 
objectives. 
 
Activities 
A full-time quality manager was recruited and took up service at the EMCDDA from 
March 1, 2001.  
 
The quality manager participated in and/or chaired the following work groups addressing 
issues with an implicit or explicit quality dimension: Corporate identity; Simplification of 
administrative procedures; Editorial board (QA in the editing process); Allocation of 
secretarial and support staff; Internalisation and externalisation of tasks; and Corporate 
training strategy. 
 
Outputs 
Quality management at the EMCDDA is still in its infancy, however a number of projects 
are in the pipeline and about to yield first results: 
 a quality model – probably combining elements of the Australian Quality Model 
and various public sector models – will be proposed to the IMCC before the end 
of 2001 and implemented in the coming year; 
 a web-based training course on QM in English, French and Portuguese will be 
made available to all EMCDDA staff; 
 an internal survey of staff satisfaction was carried out this summer. The results of 
this inquiry will help us to define measures to improve staff morale and in-house 
productivity; and 
 the external evaluation of the Reitox network accomplished by Economisti 
associati will help us to define remedies to overcome the problems identified. 
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IV – Cooperation with EU bodies and international partners 
 
Institutional liaison 
 
European Parliament 
In 2001, the EMCDDA followed discussions in the European Parliament regarding 
the EU drug phenomenon. In November, the Centre presented its 2001 Annual report 
to the Committee on Citizens’ Freedoms and Rights, Justice and Home Affairs prior 
to its official launch on 20 November.  
 
Council of the European Union 
The EMCDDA participated as an expert body, along with Europol, in all meetings of 
the Horizontal Working Party on Drugs (HWPD) of the Council of the European 
Union. The main achievements include: the adoption by the Council of a resolution 
on the five key epidemiological indicators; the unanimous opinion of the HWPD to put 
the new synthetic drug PMMA under control; and the adoption of the methodology 
recommended by the EMCDDA and Europol for an evaluation of the EU strategy on 
drugs (2000–2004). 
 
European Commission 
Cooperation with various sections of the European Commission was intensified and 
cooperation is highlighted throughout this report under the respective activity area.  
 
Directorate-General for Justice and Home Affairs: cooperation in exploring the best 
tools and ways of implement the five key epidemiological indicators.  
 
Spokesman’s Service of the European Commission: hosting of the 2001 Annual 
report press launch and news conference. 
 
Directorate-General for Health and Consumer Protection: participation in the 
Commission evaluation committee of the programme for the prevention of drug 
dependence and contribution to the advisory committee of the programme. Scientific 
assistance in the draft recommendation of the Council on drug-related risks 
reduction. 
 
Directorate-General for Research: the EMCDDA received funding from the European 
Commission’s targeted socioeconomic research (TSER) programme for a number of 
projects in the field of epidemiology. Cooperation in the DG RTD workshop on the 
priorities for drug-related research (VI Framework Programme). 
 
Eurostat: The EMCDDA cooperated closely on the topic of drug-related deaths. 
Eurostat participated in the working group on the five key indicators. 
 
European Union agencies 
The EMCDDA participated in several meetings of the EU decentralised agencies, 
and contributed to discussions on the impact of the future participation of the CEEC 
candidate countries on their work.  
 
 
International cooperation 
Objectives  
To manage relations with international organisations and with some third countries. 
 
Activities 
The EMCDDA attended a number of important international meetings in the 
perspective of the implementation of its work programme. 
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At the 44th Commission of Narcotics Drugs in Vienna, Executive Director Mr. 
Estievenart met UNDCP Executive Director Mr. Arlacchi allowing progress to be 
made on the implementation process of the Lisbon Consensus Document on 
epidemiological questions and on the revision of the Annual Report Questionnaire. 
 
The EMCDDA attended 47th and 48th Pompidou Group Permanent Correspondents 
meetings in Strasbourg, providing momentum to bilateral cooperation concerning 
candidate countries and specific epidemiology and demand reduction joint activities. 
 
At the XXIX and XX CICAD-OAS Regular sessions in Washington and Caracas, a 
number of useful contacts were made relating inter alia to the Multilateral Evaluation 
Mechanism implementation process and to the possibilities offered by the 
Coordination and Cooperation Mechanism on Drugs between the EU, Latin America 
and the Caribbean. Concerning this concrete framework, Executive Director attended 
its Third High Level Meeting in Cochabamba, where he addressed a lecture on the 
various possibilities of enhancing cooperation between the three regions. In the same 
perspective, the Executive Director attended a meeting convened by the Andean 
countries and the Spanish Authorities in Cartagena de Indias. 
 
The EMCDDA also attended 70th Interpol General Assembly in Budapest, where 
discussions took place on the future implementation of the Cooperation Agreement 
between both organisations. 
 
Finally, the EMCDDA was honoured in receiving a visit of President of Chile, Mr. 
Ricardo Lagos, in the margins of a State visit paid to Portugal. On this occasion, the 
Ambassador of Chile to Portugal, Mr. Belisario Velasco and Executive Director 
signed a Declaration of Intent concerning a number of joint cooperation activities. 
       
Outputs 
Declaration of Intent between the Government of the Republic of Chile and 
the European Monitoring Centre for Drugs and Drug Addiction. 
Cochabamba Declaration of the Third High Level meeting of the Coordination 
and Cooperation Mechanism on Drugs between the EU, Latinamerica and the 
Caribbean. 
Executive Director Lecture on Exchange of Information and Experience: 
Collecting Information. 
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Annexes 
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List of staff and functions 
 
ACTIVITY  
Director G. Estievenart   AT/A 
Secretary O. Kalomenidu   AT/C 
Secretary E. Costa    AT/C 
 
Directors Office  
Assistant K. Hernalsteen (50%)  F/A 
Institutional Liaison A. Wallon (40%)   AT/A 
International Organisations I. Vázquez Moliní (20%)  AT/A 
Management Board Support M. Blum (50%)   AT/B 
Scientific Committee Support L. Westberg (20%)   AT/B 
Bureau de Passage S. van Buggenhout   AT/C 
 
Internal communication ; interface with 
member states audiences 
G. Felgueiras    AT/A 
Targeted information provider G. Contestabile   AT/B 
Media Relations and marketing K. Robertson    AT/A 
Publications R. M. de Sousa   AT/A 
Communication and dissemination support M. J. Louro    AL 
Communication and dissemination support M. P. Koch    AL 
 
Coordination manager J. Bardolet    AT/A 
Secretary C. Reymão (50%)   AT/C 
 
Quality manager A. Tvedt    AUX 
 
PROGRAMME/ACTIVITY COORDINATOR 
Monitoring of the situation (P1) R. Hartnoll    AT/A 
Secretary M. Gomes    AT/C 
  
Projects Manager 
Prevalence and patterns of drug use among 
the general population 
J. Vicente (50%)   AT/A 
Prevalence and patterns of problem drug use L. Wiessing (50%)   AT/A 
Emerging trends in drug use and drug related 
problems 
D. Olszewski    AT/A 
Drug related infectious diseases L. Wiessing (50%)   AT/A 
Drug related deaths and mortality among 
drug users 
J. Vicente (50%)   AT/A 
Drug treatment demand L. Montanari (50%)   AT/A 
Drug related crime C. Carpentier (50%)   AT/A 
Drug related social exclusion C. Carpentier (25%)   AT/A 
Global availability of illicit drugs C. Carpentier (25%)   AT/A 
Global availability of illicit drugs I. Vázquez Moliní (30%)  AT/A 
Data bases N. Frost    AT/A 
Scientific Assistance M. Blum (50%)   AT/B 
Technical Assistance  
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PROGRAMME/ACTIVITY COORDINATOR 
Responses analysis (P2) M. Nilson    AT/A 
Secretary S. Vicente    AL 
Projects Manager 
Prevention G.Burkhart (50%)   AT/A 
Recreational settings, party scene, pill testing G. Burkhart (50%)   AT/A 
Early health responses P.P. Merino (50%)   AT/A 
Availability of treatment U. Solberg (50%)   INT 
Prevention of drug related crime P. P. Merino (50%)   AT/A 
Social rehabilitation and reintegration U. Solberg (50%)   INT 
Prevention of overdose deaths and overdose 
management 
D. Hedrich    AT/A 
Prevention of infectious diseases D. Hedrich    AT/A 
Injecting rooms/Users’ room D. Hedrich    AT/A 
Drug supply reduction I. Vázquez Moliní (50%)  AT/A 
Scientific Assistance and EDDRA C. Menier    AT/B 
 
PROGRAMME/ACTIVITY COORDINATOR 
Joint Action on New Synthetic Drugs (P3) A. Wallon (60%)  AT/A 
Secretary C. Paisana     AL 
Projects Manager 
New synthetic drugs L. Westberg (80%)   AT/B 
 
PROGRAMME/ACTIVITY COORDINATOR 
Strategies and Impact (P4) New    AT/A 
Secretary A. Moreira    AL 
Projects Manager 
National Strategies & Policies D. Ballotta    AT/A 
EU Strategies & Policies P. Roux    AT/A 
ELDD B. Hughes    AT/A 
National legislation C. Martel    AT/A 
 
PROGRAMME/ACTIVITY COORDINATOR 
REITOX and Enlargement W. Götz    AT/A 
Secretary Reitox P. Parga    AL 
Projects Manager 
REITOX Network F. Denecker    AT/B 
REITOX data quality L. Montanari (50%)   AT/A 
  
ENLARGEMENT A. Goosdeel    AT/A 
Secretary Enlargement (Phare Budget) C. Herédia    AL 
Project Manager (Phare Budget) R. Sedefov    AUX 
Administrative assistance (Phare Budget) L. Chu   AUX 
 
PROGRAMME/ACTIVITY COORDINATOR 
Information technology P. Ribeiro    AT/A 
Secretary A. Fragoso    AL 
Main domains Manager 
Databases and IT Acquisitions M. Carvalhosa   AT/A 
Online publications and Internet services A. Classen    END 
Firewall and Network …….. 
Windows NT servers F. Pires    AT/A 
PCS, Office Automation and IT Call Centre P. Lammar    AUX 
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PROGRAMME/ACTIVITY COORDINATOR 
Support services New     AT/A 
Secretary C. Reymão (50%)   AT/C 
Projects Manager 
Human and Material Resources K. Hernalsteen (50%)  F/A 
Rights and Obligations N. Bouvard    AT/B 
HR files management M. L. Rodrigues   AL 
Training programme F. Santoire (50%)   AUX 
Social services A. Van Mello    AT/C 
Material resources M. Mimoso    AT/B 
Print Shop/Technical Services N. Pombeiro    AL 
Driver J. M. Courela   AL 
Mail  L. Gomes    AL 
Reception A. Almeida (60%)   AL 
Financial and accounting management New     AT/A 
Accountant Assistant P. Jonjic    AT/B 
Financial Management N. Monseur    AT/C 
Financial Management J. P. Nkansa    AT/B 
Procedures and contracts F. Santoire (50%)   AUX 
Procedures and contracts S. Feteira    AT/C 
Planning and evaluation D. Storti    AT/A 
Budgetary planning and evaluation G. de Castro    F/B 
Documentation, archives, publications 
distribution and stockage 
 
Documentation research, Library and 
Archives 
A. S. Duarte    AT/A 
Documentation research, distribution and 
stockage 
M. C. Cristobal   AT/B 
Library support N. Martins    AT/C 
Distribution support A. Almeida (40%)   AL 
 
 
